CN1230445C - Novel human protein with function for promoting mouse NIH/313 cell transformation and coding sequence thereof - Google Patents
Novel human protein with function for promoting mouse NIH/313 cell transformation and coding sequence thereof Download PDFInfo
- Publication number
- CN1230445C CN1230445C CNB021369992A CN02136999A CN1230445C CN 1230445 C CN1230445 C CN 1230445C CN B021369992 A CNB021369992 A CN B021369992A CN 02136999 A CN02136999 A CN 02136999A CN 1230445 C CN1230445 C CN 1230445C
- Authority
- CN
- China
- Prior art keywords
- leu
- gly
- ser
- pro
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to a class of human proteins with a function of promoting 3T3 cell transformation, polynucleotide for coding the polypeptide, and a method for generating the polypeptide by a recombinant technology. The present invention also discloses an antagonist resisting the polypeptide and the therapeutic function of the antagonist. The present invention also discloses the applications of the polynucleotide for coding the class of human proteins with the function of promoting 3T3 cell transformation.
Description
Technical field
The invention belongs to biological technical field, specifically, the present invention relates to new coding and have the proteic polynucleotide of people that promote 3T3 cell transformation function, and the polypeptide of this polynucleotide encoding.The invention still further relates to the purposes and the preparation of these polynucleotide and polypeptide.
Background technology
The research of people's gene group is international focus at present, removes human chromosome DNA large scale sequencing, outside the method for expressed sequence order-checking (EST), also lacks the screening that begins from function and has the high-throughout method of functional gene.
Cancer is one of principal disease of harm humans health.In order to treat effectively and prophylaxis of tumours, people more and more pay close attention to genetic treatment of tumor at present.Therefore, this area presses for development research people albumen and the agonist/inhibitor thereof relevant with growth of cancer cells.
Summary of the invention
The purpose of this invention is to provide people's protein polypeptide that new the having of a class promote 3T3 cell transformation function with and fragment, analogue and derivative.
Another object of the present invention provides the polynucleotide of these polypeptide of coding.
Another object of the present invention provides the method for these polypeptide of production and the purposes of this polypeptide and encoding sequence.
In a first aspect of the present invention, novel isolated protein polypeptide with promotion 3T3 cell transformation function is provided, and it comprises the polypeptide of the aminoacid sequence with the group of being selected from down: SEQ ID NO:3,6,9,12,15,18,21,24,27,30,33,36,39; Or its conservative property variation polypeptide or its active fragments or its reactive derivative.
Preferably, this polypeptide is the polypeptide with aminoacid sequence of the group of being selected from down: SEQ ID NO:3,6,9,12,15,18,21,24,27,30,33,36,39.
In a second aspect of the present invention, a kind of isolating polynucleotide are provided, it comprises a nucleotide sequence, and this nucleotide sequence is shown at least 85% homogeny with a kind of nucleotides sequence that is selected from down group: the polynucleotide with the protein polypeptide that promotes 3T3 cell transformation function that (a) coding is above-mentioned; (b) with polynucleotide (a) complementary polynucleotide.Preferably, the polypeptide of this polynucleotide encoding has the aminoacid sequence of the group of being selected from down: SEQ ID NO:3,6,9,12,15,18,21,24,27,30,33,36,39.More preferably, the sequence of these polynucleotide is selected from down group: SEQ ID NO:2,5,8,11,14,17,20,23,26,29,32,35,38 coding region sequence or full length sequence.
In a third aspect of the present invention, the carrier that contains above-mentioned polynucleotide is provided, and has been transformed or host cell of transduceing or the host cell that is directly transformed or transduce by above-mentioned polynucleotide by this carrier.
In a fourth aspect of the present invention, provide preparation to have the preparation method of the polypeptide of the protein-active that promotes 3T3 cell transformation function, this method comprises: (a) being fit to express under the proteic condition with promotion 3T3 cell transformation function, cultivate the above-mentioned host cell that is transformed or transduce; (b) from culture, isolate polypeptide with the protein-active that promotes 3T3 cell transformation function.
In a fifth aspect of the present invention, provide and the above-mentioned protein polypeptide specificity bonded antibody that promotes 3T3 cell transformation function that has.The nucleic acid molecule that can be used for detecting also is provided, and it contains, and continuous 10 Nucleotide are to full length nucleotide in the above-mentioned polynucleotide, and preferably it contains the about 15-1000 of a successive Nucleotide.
In a sixth aspect of the present invention, a kind of pharmaceutical composition is provided, it contains the protein polypeptide and the pharmaceutically acceptable carrier with promotion 3T3 cell transformation function of the present invention of safe and effective amount.These pharmaceutical compositions can be used for promoting the growth of cell.The present invention also provides a kind of pharmaceutical composition, it contain safe and effective amount at antagonist (as antibody) and the pharmaceutically acceptable carrier with the protein polypeptide that promotes 3T3 cell transformation function of the present invention.This pharmaceutical composition can be treated illnesss such as cancer and cellular abnormality propagation.
Others of the present invention are because disclosing of the technology of this paper is conspicuous to those skilled in the art.
Embodiment
The 3T3 cell is a kind of l cell (J.Cell.Biol., 17:299,1963) (being also referred to as the NIH/3T3 cell).In the cancer research field, often foreign gene (especially people's gene) is introduced the 3T3 cell, observe its situation that influences to the growth of 3T3 cell.It has been generally acknowledged that, to 3T3 cell growth (or vicious transformation or transfection) influential gene is cancer related gene, wherein to 3T3 cell growth or transform that inhibiting gene is arranged is cancer suppressor gene mostly, and to the growth of 3T3 cell or transform (former) oncogene that has the gene of promoter action to be mostly.
The present invention adopts large-scale cDNA clone transfection mouse embryo fibroblasts 3T3, has on the basis that promotes the growth effect in acquisition, proves new gene through order-checking, further obtains full length cDNA clone.DNA transfection evidence, the albumen with promotion 3T3 cell transformation function of the present invention has the effect that promotes that the clone forms, its promotion rate 〉=50% to the 3T3 cell.
As used herein, " isolating " is meant that material separates (if natural substance, primal environment promptly is a natural surroundings) from its primal environment.Do not have separation and purification as polynucleotide under the native state in the active somatic cell and polypeptide, but same polynucleotide or polypeptide as from native state with in other materials that exist separately, then for separation and purification.
As used herein, " isolating albumen or polypeptide with promotion 3T3 cell transformation function " is meant to have and promotes the protein polypeptide of 3T3 cell transformation function to be substantially free of natural relative other albumen, lipid, carbohydrate or other material.Those skilled in the art can have the albumen that promotes 3T3 cell transformation function with the purified technology of protein purifying of standard.Basically pure polypeptide can produce single master tape on non-reduced polyacrylamide gel.
Polypeptide of the present invention can be recombinant polypeptide, natural polypeptides, synthetic polypeptide, preferred recombinant polypeptide.Polypeptide of the present invention can be the product of natural purifying, or the product of chemosynthesis, or uses recombinant technology to produce from protokaryon or eucaryon host (for example, bacterium, yeast, higher plant, insect and mammalian cell).The host used according to the recombinant production scheme, polypeptide of the present invention can be glycosylated, maybe can be nonglycosylated.Polypeptide of the present invention also can comprise or not comprise initial methionine residues.
The present invention also comprises having the proteic fragment of people, derivative and the analogue that promotes 3T3 cell transformation function.As used herein, term " fragment ", " derivative " are meant with " analogue " and keep natural identical biological function or the active polypeptide of people's albumen that promotes 3T3 cell transformation function that have of the present invention basically.Polypeptide fragment of the present invention, derivative or analogue can be that (i) has one or more conservative or substituted polypeptide of non-conservation amino-acid residue (preferred conservative amino acid residue), and the amino-acid residue of such replacement can be also can not encoded by genetic code, or (ii) in one or more amino-acid residues, has a polypeptide of substituted radical, or (iii) mature polypeptide and another compound (such as the compound that prolongs the polypeptide transformation period, polyoxyethylene glycol for example) merge formed polypeptide, or (iv) additional aminoacid sequence is fused to this peptide sequence and the polypeptide that forms (as leader sequence or secretion sequence or be used for the sequence or the proteinogen sequence of this polypeptide of purifying).According to the instruction of this paper, these fragments, derivative and analogue belong to the known scope of those skilled in the art.
Polynucleotide of the present invention can be dna form or rna form.Dna form comprises the DNA of cDNA, genomic dna or synthetic.DNA can be strand or double-stranded.DNA can be coding strand or noncoding strand.Be example with FP17548 albumen (in this application, its clone numbering is adopted in proteinic name), the coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:2 or the varient of degeneracy.As used herein, " varient of degeneracy " is meant that for FP17548 coding has the protein of SEQ ID NO:3, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ ID NO:2.Be example with FP17581 albumen again, the coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:5 or the varient of degeneracy.As used herein, " varient of degeneracy " is meant that for FP17581 coding has the protein of SEQ ID NO:6, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ ID NO:5.Other have the albumen that promotes 3T3 cell transformation function for the present invention, and the rest may be inferred.
The polynucleotide of encoding mature polypeptide comprise: the encoding sequence of an encoding mature polypeptide; The encoding sequence of mature polypeptide and various additional code sequence; Encoding sequence of mature polypeptide (with optional additional code sequence) and non-coding sequence.
Term " polynucleotide of coded polypeptide " can be the polynucleotide that comprise this polypeptide of encoding, and also can be the polynucleotide that also comprise additional code and/or non-coding sequence.
The invention still further relates to the varient of above-mentioned polynucleotide, its coding has the polypeptide of identical aminoacid sequence or fragment, analogue and the derivative of polypeptide with the present invention.The varient of these polynucleotide can be the allelic variant of natural generation or the varient that non-natural takes place.These nucleotide diversity bodies comprise and replace varient, deletion mutation body and insert varient.As known in the art, allelic variant is the replacement form of polynucleotide, and it may be replacement, disappearance or the insertion of one or more Nucleotide, but can be from not changing the function of its encoded polypeptides in fact.
The invention still further relates to and above-mentioned sequence hybridization and two sequences between have at least 50%, preferably at least 70%, the polynucleotide of at least 80% homogeny more preferably.The present invention be more particularly directed under stringent condition and the interfertile polynucleotide of polynucleotide of the present invention.In the present invention, " stringent condition " is meant: (1) than hybridization under low ionic strength and the comparatively high temps and wash-out, as 0.2 * SSC, and 0.1%SDS, 60 ℃; Or (2) hybridization the time is added with denaturing agent, as 50% (v/v) methane amide, 0.1% calf serum/0.1% Ficoll, 42 ℃ etc.; Or (3) only at the homogeny between the two sequences at least more than 95%, be more preferably 97% and just hybridize when above.And the polypeptide of interfertile polynucleotide encoding has identical biological function and activity with the mature polypeptide shown in the SEQ IDNO:3 (is example with FP17548 albumen).
The invention still further relates to nucleic acid fragment with above-mentioned sequence hybridization.As used herein, the length of " nucleic acid fragment " contains 15 Nucleotide at least, better is at least 30 Nucleotide, is more preferably at least 50 Nucleotide, preferably more than at least 100 Nucleotide.The amplification technique (as PCR) that nucleic acid fragment can be used for nucleic acid has the proteic polynucleotide that promotes 3T3 cell transformation function to determine and/or to separate coding.
Polypeptide among the present invention and polynucleotide preferably provide with isolating form, more preferably are purified to homogeneous.
Dna sequence dna of the present invention can obtain with several method.For example, with hybridization technique DNA isolation well known in the art.These technology including, but not limited to: 1) with probe and genome or the hybridization of cDNA library to detect homology nucleotide sequence and 2) antibody screening of expression library to be to detect the dna fragmentation of the clone with common structure feature.
Coding has the proteic specific DNA fragment sequence that promotes 3T3 cell transformation function and produces also and can obtain with following method: 1) separate double chain DNA sequence from genomic dna; 2) the chemical synthesising DNA sequence is to obtain the double-stranded DNA of required polypeptide.
When the whole aminoacid sequence of the polypeptide product of needs was known, the direct chemical of dna sequence dna is synthetic to be the method for often selecting for use.When if required amino acid whose whole sequence is not known, the direct chemical of dna sequence dna is synthetic to be impossible, and the method for selecting for use is the separation of cDNA sequence.The standard method that separates interested cDNA is from the donorcells separating mRNA of this gene of high expression level and carries out reverse transcription, forms plasmid or phage cDNA library.Extract the existing multiple proven technique of method of mRNA, test kit also can obtain (Qiagene) from commercial channels.And the construction cDNA library also is usual method (Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring HarborLaboratory.New York, 1989).Also can obtain the cDNA library of commercial offers, as the different cDNA library of Clontech company.When being used in combination the polymeric enzyme reaction technology, even few expression product also can be cloned.
Available ordinary method is screened gene of the present invention from these cDNA libraries.These methods include, but is not limited to: (1) DNA-DNA or DNA-RNA hybridization; (2) function of marker gene occurs or forfeiture; (3) measure level with the proteic transcript that promotes 3T3 cell transformation function; (4), detect the protein product of genetic expression by immunological technique or mensuration biologic activity.Aforesaid method can singly be used, but also several different methods combined utilization.
In (1) kind method, hybridizing used probe is and any a part of homology of polynucleotide of the present invention that at least 15 Nucleotide of its length better are at least 30 Nucleotide, are more preferably at least 50 Nucleotide, preferably at least 100 Nucleotide.In addition, the length of probe within 2kb, preferably is within the 1kb usually.Probe used herein is the dna sequence dna of chemosynthesis on the basis of gene DNA sequence information of the present invention normally.Gene of the present invention itself or fragment are certainly as probe.The mark of dna probe can be used radio isotope, fluorescein or enzyme (as alkaline phosphatase) etc.
In (4) kind method, detect protein product and can use immunological technique such as Western blotting, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA) etc. with the protein gene expression that promotes 3T3 cell transformation function.
Use method (Saiki, the et al.Science 1985 of round pcr DNA amplification/RNA; 230:1350-1354) be optimized for acquisition gene of the present invention.When particularly being difficult to obtain the cDNA of total length from the library, can preferably use RACE method (the terminal rapid amplifying method of RACE-cDNA), the primer that is used for PCR can suitably be selected according to sequence information of the present invention disclosed herein, and available ordinary method is synthetic.Available ordinary method is as the DNA/RNA fragment by gel electrophoresis separation and purifying amplification.
The gene of the present invention that obtains as mentioned above, perhaps the available ordinary method of mensuration of the nucleotide sequence of various dna fragmentations etc. such as dideoxy chain termination (Sanger et al.PNAS, 1977,74:5463-5467).This class nucleotide sequencing is available commercial sequencing kit etc. also.In order to obtain the cDNA sequence of total length, order-checking need be carried out repeatedly.Sometimes need to measure a plurality of clones' cDNA sequence, just can be spliced into the cDNA sequence of total length.
The present invention also relates to comprise the carrier of polynucleotide of the present invention, and with carrier of the present invention or have the host cell that the albumen coded sequence that promotes 3T3 cell transformation function produces through genetically engineered, and the method that produces polypeptide of the present invention through recombinant technology.
Recombinant DNA technology (Science, 1984 by routine; 224:1431), can utilize polymerized nucleoside acid sequence of the present invention to can be used to express or produce the protein polypeptide that promotes 3T3 cell transformation function that has of reorganization.In general following steps are arranged:
(1). have the proteic polynucleotide of people (or varient) that promote 3T3 cell transformation function with coding of the present invention, or transform or the transduction proper host cell with the recombinant expression vector that contains these polynucleotide;
(2). the host cell of in suitable medium, cultivating;
(3). separation, protein purification from substratum or cell.
Among the present invention, the people's albumen polynucleotide sequence with promotion 3T3 cell transformation function can be inserted in the recombinant expression vector.Term " recombinant expression vector " refers to that bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell virus, mammalian cell virus are as adenovirus, retrovirus or other carriers.The carrier of Shi Yonging includes but not limited in the present invention: and the expression vector based on T7 of in bacterium, expressing (Rosenberg, et al.Gene, 1987,56:125); The pMSXND expression vector of in mammalian cell, expressing (Lee and Nathans, J Bio Chem.263:3521,1988) and at the carrier that derives from baculovirus of expressed in insect cells.In a word, as long as can duplicate in host and stablize, any plasmid and carrier can be used.A key character of expression vector is to contain replication orgin, promotor, marker gene and translation controlling elements usually.
Method well-known to those having ordinary skill in the art can be used to make up contain and has people's encoding histone dna sequence dna of promoting 3T3 cell transformation function and suitable transcribing/translate the expression vector of control signal.These methods comprise (Sambroook, et al) such as extracorporeal recombinant DNA technology, DNA synthetic technology, the interior recombinant technologys of body.Described dna sequence dna can effectively be connected on the suitable promotor in the expression vector, and is synthetic to instruct mRNA.The representative example of these promotors has: colibacillary lac or trp promotor; Lambda particles phage P
LPromotor; Eukaryotic promoter comprises CMV immediate early promoter, early stage and late period SV40 promotor and some other known may command gene expression promoter in protokaryon or eukaryotic cell or its virus.Expression vector also comprises ribosome bind site and the transcription terminator that translation initiation is used.
In addition, expression vector preferably comprises one or more selected markers, to be provided for selecting the phenotypic character of transformed host cells, cultivate Tetrahydrofolate dehydrogenase, neomycin resistance and the green fluorescent protein (GFP) of usefulness as eukaryotic cell, or be used for colibacillary tsiklomitsin or amicillin resistance.
Comprise the carrier of above-mentioned suitable dna sequence dna and suitable promotor or control sequence, can be used to transform appropriate host cell, so that it can marking protein.
Host cell can be a prokaryotic cell prokaryocyte, as bacterial cell; Or eukaryotic cell such as low, as yeast cell: or higher eucaryotic cells, as mammalian cell.Representative example has: intestinal bacteria, streptomyces; The bacterial cell of Salmonella typhimurium; Fungal cell such as yeast; Vegetable cell; The insect cell of fruit bat S2 or Sf9; The zooblast of CHO, COS or Bowes melanoma cells etc.
When polynucleotide of the present invention are expressed in higher eucaryotic cells, be enhanced if will make to transcribe when in carrier, inserting enhancer sequence.Enhanser is the cis acting factor of DNA, and nearly 10 to 300 base pairs act on promotor transcribing with enhancing gene usually.Can for example be included in the SV40 enhanser of 100 to 270 base pairs of replication origin side in late period one, at the polyoma enhanser of replication origin side in late period one and adenovirus enhanser etc.
Persons skilled in the art all know how to select appropriate carriers, promotor, enhanser and host cell.
Can carry out with routine techniques well known to those skilled in the art with the recombinant DNA transformed host cell.When the host was prokaryotic organism such as intestinal bacteria, the competent cell that can absorb DNA can be used CaCl in exponential growth after date results
2Method is handled, and used step is well-known in this area.Alternative is to use MgCl
2If desired, transforming also the method for available electroporation carries out.When the host is an eukaryote, can select following DNA transfection method for use: coprecipitation of calcium phosphate method, conventional mechanical method such as microinjection, electroporation, liposome packing etc.
The transformant that obtains can be cultivated with ordinary method, expresses the polypeptide of coded by said gene of the present invention.According to used host cell, used substratum can be selected from various conventional substratum in the cultivation.Under the condition that is suitable for the host cell growth, cultivate.After host cell grows into suitable cell density, induce the promotor of selection with suitable method (as temperature transition or chemical induction), cell is cultivated for some time again.
Recombinant polypeptide in the above methods can wrap by in cell, extracellular or on cytolemma, express or be secreted into the extracellular.If desired, can utilize its physics, the separating by various separation methods with other characteristic and the albumen of purification of Recombinant of chemistry.These methods are well-known to those skilled in the art.The example of these methods includes, but are not limited to: conventional renaturation handles, with protein precipitant handle (salt analysis method), centrifugal, the broken bacterium of infiltration, superly handle, the combination of super centrifugal, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods.
Having of reorganization promotes the people's albumen or the polypeptide of 3T3 cell transformation function to be of use in many ways.These purposes include, but is not limited to: directly have the disease due to the low or forfeiture of the protein function that promotes 3T3 cell transformation function as pharmacological agent and be used to screen and promote or antagonism has antibody, polypeptide or other part of the protein function that promotes 3T3 cell transformation function.For example, this antibody can be used for treating cancer or cellular abnormality propagation.The peptide molecule that can suppress or stimulate people's protein function that can be used for seeking therapeutic value with recombinant expressed protein screening peptide library of the present invention with promotion 3T3 cell transformation function.
The present invention also provides screening of medicaments to improve (agonist) or check the method that (antagonist) has the proteic medicament of people that promotes 3T3 cell transformation function to identify.Agonist improves and to have the people's albumen that promotes 3T3 cell transformation function biological function such as stimulate cellular proliferation, and antagonist prevention disorder such as the various cancer relevant with cell hyperproliferation with treatment.
Have the proteic antagonist of people that promotes 3T3 cell transformation function and comprise antibody, compound, acceptor disappearance thing and the analogue etc. that filter out.Have the proteic antagonist of people that promotes 3T3 cell transformation function and can and eliminate its function with people's protein binding with promotion 3T3 cell transformation function, or suppress to have the proteic generation of people that promotes 3T3 cell transformation function, or combine with the avtive spot of polypeptide and to make polypeptide can not bring into play biological function.Have and promote the proteic antagonist of people of 3T3 cell transformation function to can be used for therepic use.
In screening during as the compound of antagonist, can add in the bioanalysis mensuration having the albumen that promotes 3T3 cell transformation function, the albumen and the interaction between its acceptor that have promotion 3T3 cell transformation function by the mensuration compounds affect determine whether compound is antagonist.With the same quadrat method of above-mentioned SCREENED COMPOUND, can filter out the acceptor disappearance thing and the analogue of antagonist action.
The proteic antagonist of the present invention can be directly used in disease treatment, for example, and various malignant tumours and cellular abnormality propagation etc.
Polypeptide of the present invention, and fragment, derivative, analogue or their cell can be used as antigen to produce antibody.These antibody can be polyclone or monoclonal antibody.Polyclonal antibody can obtain by the method with this polypeptide direct injection animal.The technology of preparation monoclonal antibody comprises hybridoma technology, three knurl technology, people B-quadroma technology, EBV-hybridoma technology etc.
Can be with polypeptide of the present invention and antagonist and suitable pharmaceutical carrier combination back use.These carriers can be water, glucose, ethanol, salt, damping fluid, glycerine and their combination.Composition comprises the polypeptide or the antagonist of safe and effective amount and carrier and the vehicle that does not influence effect of drugs.These compositions can be used as medicine and are used for disease treatment.
The present invention also provides medicine box or the test kit that contains one or more containers, and one or more medicinal compositions compositions of the present invention are housed in the container.With these containers, can have by the given indicative prompting of government authorities of making, using or selling medicine or biological products, the government authorities that this prompting reflects production, uses or sells permits it to use on human body.In addition, polypeptide of the present invention can be used in combination with other treatment compound.
Pharmaceutical composition can be with mode administration easily, as by in part, intravenously, intraperitoneal, intramuscular, subcutaneous, the nose or the route of administration of intracutaneous.Have the albumen or its specific antibody that promote 3T3 cell transformation function, can come administration by the amount that treats and/or prevents concrete indication effectively.Be applied to having of patient and promote the proteic amount and the dosage range of 3T3 cell transformation function will depend on many factors, as administering mode, person's to be treated healthiness condition and diagnostician's judgement.
Have and promote the proteic polynucleotide of people of 3T3 cell transformation function also to can be used for multiple therapeutic purpose.Gene therapy technology can be used for treating since have that the proteic nothing that promotes 3T3 cell transformation function is expressed or unusual/non-activity have cell development or a metabolic disturbance due to the proteic expression that promotes 3T3 cell transformation function.The gene therapy vector (as virus vector) of reorganization can be designed to express the albumen that promotes 3T3 cell transformation function that has of variation, to suppress the endogenic protein-active that promotes 3T3 cell transformation function that has.For example, a kind of albumen that promotes 3T3 cell transformation function that has of variation can be the albumen with promotion 3T3 cell transformation function that shortens, lacked signal conduction function territory, though can combine with the substrate in downstream, lacks signaling activity.Therefore the gene therapy vector of reorganization can be used for treating and has the protein expression that promotes 3T3 cell transformation function or the disease of active caused by abnormal.Deriving from the expression vector of virus such as retrovirus, adenovirus, adeno-associated virus (AAV), hsv, parvovirus etc. can be used for having and promotes the protein gene of 3T3 cell transformation function to be transferred in the cell.The method that structure carries the recombinant viral vector with the protein gene that promotes 3T3 cell transformation function is found in existing document (Sambrook, et al.).Reorganization has the people's protein gene that promotes 3T3 cell transformation function and can be packaged in the liposome and be transferred in the cell in addition.
Inhibition has the oligonucleotide (comprising sense-rna and DNA) of the people's protein mRNA that promotes 3T3 cell transformation function and ribozyme also within the scope of the invention.Ribozyme is the enzyme sample RNA molecule that a kind of energy specificity is decomposed specific RNA, and its mechanism of action is to carry out the endonuclease effect after ribozyme molecule and the hybridization of complementary target RNA-specific.The RNA of antisense and DNA and ribozyme can obtain with existing any RNA or DNA synthetic technology, as the technology widespread use of solid phase phosphoamide chemical synthesis synthetic oligonucleotide.Antisense rna molecule can be transcribed acquisition by the dna sequence dna of this RNA that encodes in external or body.This dna sequence dna has been incorporated into the downstream of rna polymerase promoter of carrier.In order to increase the stability of nucleic acid molecule, available several different methods is modified it, and as increasing the sequence length of both sides, the connection between the ribonucleoside is used phosphoric acid thioester bond or peptide bond but not phosphodiester bond.
Polynucleotide imports tissue or intracellular method comprises: directly be injected into polynucleotide in the in-vivo tissue; Or external by carrier (as virus, phage or plasmid etc.) earlier with the polynucleotide transfered cell in, again cell is transplanted in the body etc.Because albumen of the present invention has the function that promotes the 3T3 cell transformation, so the antisense sequences of albumen coded sequence of the present invention, can be introduced into cell to suppress the abnormality proliferation (as canceration) of cell.
The present invention also provides at the antibody with the people's proteantigen determinant that promotes 3T3 cell transformation function.These antibody include, but is not limited to: the fragment that polyclonal antibody, monoclonal antibody, chimeric antibody, single-chain antibody, Fab fragment and Fab expression library produce.
The anti-proteic antibody of people with promotion 3T3 cell transformation function can be used in the immunohistochemistry technology, detects the people's albumen that promotes 3T3 cell transformation function that has in the biopsy specimen.
The also available labelled with radioisotope of the protein bound monoclonal antibody of people with having promotion 3T3 cell transformation function injects in the body and can follow the tracks of its position and distribution.This radiolabeled antibody can be used as a kind of atraumatic diagnostic method and is used for the location of tumour cell and has judged whether transfer.
Antibody among the present invention can be used for treating or preventing and have the relevant disease of people's albumen of promotion 3T3 cell transformation function.The antibody that gives suitable dosage can be blocked proteic generation of people or the activity with promotion 3T3 cell transformation function, thus the abnormality proliferation of the growth of anticancer and/or cell.
Antibody also can be used for designing the immunotoxin at a certain privileged sites in the body.As have the people's albumen high-affinity that promotes 3T3 cell transformation function monoclonal antibody can with bacterium or plant poison (as diphtheria toxin, ricin, abrine etc.) covalent attachment.A kind of usual method is with sulfydryl linking agent such as SPDP, attacks the amino of antibody, by the exchange of disulfide linkage, toxin is incorporated on the antibody, and this hybrid antibody can be used for killing relevant positive cell (as cancer cells).
Available people's albumen or the polypeptide immune animal of the production of polyclonal antibody with promotion 3T3 cell transformation function, as rabbit, mouse, rat etc.Multiple adjuvant can be used for the enhancing immunity reaction, includes but not limited to freund's adjuvant etc.
Have promote 3T3 cell transformation function people's protein monoclonal antibody can with hybridoma technology production (Kohler andMilstein.Nature, 1975,256:495-497).With the variable region bonded chimeric antibody in human constant region and inhuman source can with existing technology production (Morrison et al, PNAS, 1985,81:6851).And the technology of existing manufacture order chain antibody (U.S.Pat No.4946778) also can be used for producing the anti-proteic single-chain antibody of people that promotes 3T3 cell transformation function that has.
Can with have the protein bound peptide molecule of people that promotes 3T3 cell transformation function and can be incorporated into the rondom polypeptide storehouse that solid formation forms by the various amino acid that may make up by screening and obtain.During screening, must promote people's protein molecular of 3T3 cell transformation function to carry out mark to having.
The invention still further relates to quantitatively and detection and localization has the diagnostic testing process of people's protein level of promotion 3T3 cell transformation function.These tests are known in the art, and comprise that FISH measures and radioimmunoassay.That is detected in the test has a protein level that promotes 3T3 cell transformation function, can have the importance of albumen in various diseases that promotes 3T3 cell transformation function with laying down a definition and be used to diagnose to have the disease that the albumen that promotes 3T3 cell transformation function works.
Proteic polynucleotide with promotion 3T3 cell transformation function can be used for having the diagnosis and the treatment of the protein related diseases that promotes 3T3 cell transformation function.Aspect diagnosis, have the proteic polynucleotide that promotes 3T3 cell transformation function can be used for detecting have promote 3T3 cell transformation function proteic expression whether or under morbid state, have an abnormal exprssion that promotes 3T3 cell transformation function.As the protein D NA sequence with promotion 3T3 cell transformation function can be used for that the hybridization of biopsy specimen is had the proteic abnormal expression that promotes 3T3 cell transformation function with judgement.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (Microarray) or DNA chip (being gene chip), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.Carry out RNA-polymerase chain reaction (RT-PCR) amplification in vitro with the special primer of albumen and also can detect proteic transcription product with promotion 3T3 cell transformation function with promotion 3T3 cell transformation function.
The sudden change that detection has the protein gene that promotes 3T3 cell transformation function also can be used for diagnosing the relevant disease of albumen with promotion 3T3 cell transformation function.Form with the protein mutation that promotes 3T3 cell transformation function comprises that to have point mutation that the protein D NA sequence that promotes 3T3 cell transformation function compares, transposition, disappearance, reorganization and other any unusual etc. with normal wild type.Available existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization detect sudden change.In addition, sudden change might influence proteic expression, therefore can judge indirectly that with Northern blotting, Western blotting gene has or not sudden change.
Sequence of the present invention identifies it also is valuable to karyomit(e).These sequences can be specifically at certain bar human chromosome particular location and and can with its hybridization.At present, need to identify the concrete site of each gene on the karyomit(e).Yet have only chromosomal marker thing seldom to can be used for the marker chromosomes position now based on actual sequence data (repetition polymorphism).For these sequences are associated with disease related gene.The first step is positioned dna sequence dna of the present invention on the karyomit(e) exactly.
In brief, prepare PCR primer (preferred 15-35bp), sequence can be positioned on the karyomit(e) according to cDNA.Then, these primers are used for the somatocyte hybrid cell that the PCR screening contains each bar human chromosome.Have only those hybrid cells that contain corresponding to the people's gene of primer can produce the fragment of amplification.
The PCR localization method of somatocyte hybrid cell is that DNA is navigated to concrete chromosomal quick method.Use Oligonucleolide primers of the present invention,, can utilize one group to realize inferior location from specific chromosomal fragment or a large amount of genomic clone by similar approach.Other the similar strategy that can be used for chromosomal localization comprises in situ hybridization, uses the karyomit(e) prescreen and the hybridization preliminary election of the airflow classification of mark, thereby makes up the special cDNA storehouse of karyomit(e).
The cDNA clone is carried out fluorescence in situ hybridization (FISH) with Metaphase Chromosome, can in a step, accurately carry out chromosomal localization.The summary of this technology is referring to Verma etc., Human Chromosomes:a Manual of BasicTechniques, Pergamon Press, New York (1988).
In case sequence is positioned to chromosome position accurately, the physical location of this sequence on karyomit(e) just can be associated with the gene map data.These data for example are found in, V.Mckusick, Mendelian Inheritance in Man (can by with the online acquisition of Johns Hopkins University Welch Medical Library).Can pass through linkage analysis then, determine gene and navigated to relation between the disease on the chromosomal region already.
Then, need to measure ill and not cDNA between diseased individuals or genome sequence difference.If observe certain sudden change in some or all of diseased individuals, and this sudden change is not observed in any normal individual, then this sudden change may be the cause of disease of disease.More ill and diseased individuals not is usually directed at first seek the variation of structure in the karyomit(e), as from the horizontal visible of karyomit(e) or use based on detectable disappearance of the PCR of cDNA sequence or transposition.
Pyrenoids thuja acid full length sequence or its fragment with promotion 3T3 cell transformation function of the present invention can obtain with the method for pcr amplification method, recombination method or synthetic usually.For the pcr amplification method, can be disclosed according to the present invention about nucleotide sequence, especially open reading frame sequence designs primer, and with commercially available cDNA storehouse or by the prepared cDNA storehouse of ordinary method well known by persons skilled in the art as template, amplification and must relevant sequence.When sequence is longer, usually needs to carry out twice or pcr amplification repeatedly, and then the fragment that each time amplifies is stitched together by proper order.
In case obtained relevant sequence, just can obtain relevant sequence in large quantity with recombination method.This normally is cloned into carrier with it, changes cell again over to, separates obtaining relevant sequence then from the host cell after the propagation by ordinary method.
In addition, also the method for available synthetic is synthesized relevant sequence, especially fragment length more in short-term.Usually, by first synthetic a plurality of small segments, and then connect and to obtain the very long fragment of sequence.
At present, can be fully come the dna sequence dna of code book invention albumen (or its fragment, or derivatives thereof) by chemosynthesis.This dna sequence dna can be introduced then in the various dna moleculars (as carrier) and cell in this area.In addition, also can will suddenly change and introduce in the protein sequence of the present invention by chemosynthesis.
Because the albumen with promotion 3T3 cell transformation function of the present invention has the natural acid sequence that is derived from the people, therefore, compare with the albumen of the same clan that derives from other species, estimate fashionablely will have higher active and/or lower side effect (for example in the intravital immunogenicity of people lower or do not have) being applied to.
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:Cold Spring Harbor LaboratoryPress, 1989) condition described in, or the condition of advising according to manufacturer.Notice that in Nucleotide and amino acid composite sequence, what (1) provided is the position that initial sum stops first Nucleotide of coding, (2) molecular weight unit is dalton.
The acquisition of embodiment 1:cDNA gene and the promoter action that mouse NIH/3T3 cell clone is formed
FP17548, FP17581 and FP17780 come from the human fetal cDNA library that makes up with ordinary method; LP2254, LP2261, LP2477, LP2537, LP2561, LP2642, LP2698, LP2709, LP3663 and LP3727 come from the normal hepatocytes cDNA library that makes up with ordinary method.Method is as follows: get fetal tissue (FP clone) or normal liver tissue (LP clone), (GIBCO BRL company) extracts total RNA by manufacturer's specification sheets with Trizol reagent, extracts mRNA with the mRNA test kit (Pharmacia company) of purifying.Make up the cDNA library of above-mentioned mRNA with pCMV-script TMXR cDNA library construction test kit (Stratagene company).Wherein ThermoScript II is used MMLV-RT-Superscript II (GIBCO BRL) instead, and reverse transcription reaction carries out at 42 ℃.Transform XL 10-Gold recipient cell, obtained 1 * 10
6The cDNA library of cfu/ μ g titre.The first round is picking cDNA clone at random, is probe with high abundance cDNA clone with the cDNA clone who has proved anticancer growth function thereafter, screening by hybridization cDNA library, weak positive and negative clone of picking.With Qiagen 96 orifice plate plasmid extraction test kits, carry out the extraction of plasmid DNA by shop instruction.Plasmid DNA and empty carrier transfection simultaneously mouse NIH/3T3 cell.After the 100ng DNA alcohol precipitation drying, add 6 μ l H
2Transfection is treated in the O dissolving.Add 0.74 μ l liposome and 9.3 μ l serum-free mediums in every part of DNA sample, behind the mixing, room temperature was placed 10 minutes.Add 150 μ l serum-free mediums in every pipe, divide equally and add 3 holes and grow in the mouse NIH/3T3 cell of 96 orifice plates, placed 2 hours for 37 ℃, every hole adds 50 μ l serum-free mediums again, 37 ℃ 24 hours.Every hole is changed 100 μ l and is trained liquid entirely, 37 ℃ 24 hours, change the full training liquid 100 μ l that contain G418,37 ℃ 24-48 hour, the limit is observed, the training liquid that G418 concentration does not wait is changed on the limit.After about 2-3 time, there is the clone to form up to the microscopy cell, counting.Find that above-mentioned clone has the NIH/3T3 of promotion cell clone formation effect, the result is as shown in the table.
CDNA clone's transfectional cell (3T3) clone formation situation
| CDNA clones title | CDNA clones number (three repetitions) | Empty carrier clone number (three repetitions) | ||||
| FP17548 | 60 | 62 | 48 | 7 | 34 | 10 |
| FP17581 | 37 | 34 | 30 | 7 | 34 | 10 |
| FP17780 | 42 | 59 | 68 | 19 | 19 | 21 |
| LP2254 | 55 | 59 | 50 | 4 | 9 | 13 |
| LP2261 | 50 | 56 | 52 | 4 | 9 | 13 |
| LP2477 | 71 | 55 | 70 | 29 | 22 | 27 |
| LP2537 | 80 | 75 | 82 | 29 | 22 | 27 |
| LP2561 | 58 | 60 | 65 | 22 | 25 | 29 |
| LP2642 | 49 | 54 | 57 | 22 | 25 | 29 |
| LP2698 | 45 | 42 | 44 | 22 | 25 | 29 |
| LP2709 | 46 | 42 | 58 | 22 | 25 | 29 |
| LP3663 | 70 | 60 | 55 | 28 | 45 | 33 |
| LP3727 | 49 | 41 | 52 | 28 | 45 | 33 |
The cDNA clone is adopted two deoxidation cessation method, on the ABI377 automatic dna sequencer, measure the nucleotide sequence of the nearly 500bp of one end.After the analysis, be defined as novel gene cloning, carry out the other end order-checking, do not obtain full length cDNA sequence yet, the design primer checks order once more, up to obtaining full length sequence (SEQ ID NO:1,4,7,10,13,16,19,22,25,28,31,34,37).
Embodiment 2: PCR obtains full-length gene from placenta or normal hepatocytes cDNA:
Get fetal tissue (FP clone) or normal liver tissue (LP clone), (GIBCO BRL company) extracts total RNA by manufacturer's specification sheets with Trizol reagent, extracts mRNA with the mRNA test kit (Pharmacia company) of purifying.With MMLV-RT-Superscript II (GIBCO BRL), ThermoScript II is carried out reverse transcription reaction at 42 ℃, obtains placenta or fetus cDNA.Utilize the special primer (as shown in the table) of each gene, by 97 ℃ of 3 ' 1 circulation.94 ℃ 30 " 60 ℃ 30 " 72 ℃ of 1 ' 35 circulation, pcr amplification is carried out in 72 ℃ of 10 ' 1 circulation, and acquisition contains the amplified production of each protein gene of complete open reading frame sequence.Amplified production is through sequence verification, and the sequence that records with embodiment 1 conforms to, and changes amplified production over to host cell with routine techniques subsequently, obtains recombinant protein (SEQ ID NO:3,6,9,12,15,18,21,24,27,30,33,36,39).
Gene specific primer
| Clone's title | Special primer 1 (5 ' → 3 ') | SEQ ID NO | Special primer 2 (3 ' → 5 ') | SEQ ID NO |
| FP17548 | (46)ACCCGAGCCAAGGACACC | 40 | AGAAGGGAGGGGACACGA(2584) | 41 |
| FP17581 | (151)CATTTGAAAAGCATGGTCCTAG | 42 | GGAACGACGCCTCTTACT(1716) | 43 |
| FP17780 | (158)AATCTTCCCGTTGCTGTATGTG | 44 | TTCACGGAGCCTACCACC(2199) | 45 |
| LP2254 | (63)TTTAGTGCCTCCCACCCAG | 46 | TGACCCAGAAGTGAAGAACCC(1507) | 47 |
| LP2261 | (281)CAGGGGCAAGGCACCATC | 48 | CAAGCGGGTCACGGTGCA(1096) | 49 |
| LP2477 | (81)CTAGAAGTGGAACTGCTGGGTC | 50 | TGTTTTGTTTACGGGGTCC(1585) | 51 |
| LP2537 | (16)GCGGCTCCTGTTGCTCCT | 52 | CATCCTGGGCGTCCCTGGT(993) | 53 |
| LP2561 | (117)ACCAGAGGTTGGGAGGCA | 54 | GCTTGACCTTGTAGACCAGG(146) | 55 |
| LP2642 | (14)TGGCAAGAAAGAGTGGAAGC | 56 | TGATAGGTTTAGGAGGTGACCA(1040) | 57 |
| LP2698 | (1)GCCAGGTACAGCAAGTGGG | 58 | CAAAAGAGCGTAAAAGGTGG(1218) | 59 |
| LP2709 | (8)GCCAGGCATCCTCAAATCC | 60 | TCACTCGGCTCTAACACCG(1174) | 61 |
| LP3663 | (24)GGCTCTGAGGAGGCGTTGA | 62 | AAGTTGGGTCCACGGGGA(1211) | 63 |
| LP3727 | (137)ACGTAGCGCAACGGACAG | 64 | TTATTTCAGCTCTGAGACGGCG(1186) | 65 |
Annotate: in the bracket is the correspondence position of primer in each gene DNA sequence.
Embodiment 3:cDNA cloned sequence is analyzed
1.FP17548
A: nucleotide sequence (SEQ ID NO:1) length: 2748 bases
B: aminoacid sequence (SEQ ID NO:3) length: 216 amino acid
C. Nucleotide and amino acid composite sequence (SEQ ID NO:2) clone number and protein name: FP17548
Start code: 1856 ATG stop coding: 2504 TGA protein molecular weights: 23817.56
2.FP17581
A: nucleotide sequence (SEQ ID NO:4) length: 2070 bases
B: aminoacid sequence (SEQ ID NO:6) length: 113 amino acid
C. Nucleotide and amino acid composite sequence (SEQ ID NO:5) clone number and protein name: FP17581
Start code: 676 ATG stop coding: 1015 TGA protein molecular weights: 12295.65
3.FP17780
A: nucleotide sequence (SEQ ID NO:7) length: 2392 bases
B: aminoacid sequence (SEQ ID NO:9) length: 140 amino acid
C. Nucleotide and amino acid composite sequence (SEQ ID NO:8) clone number and protein name: FP17780
Start code: 1073 ATG stop coding: 1493 TGA protein molecular weights: 15107.42
4.LP2254
A: nucleotide sequence (SEQ ID NO:10) length: 1551 bases
B: aminoacid sequence (SEQ ID NO:12) length: 229 amino acid
C. Nucleotide and amino acid composite sequence (SEQ ID NO:11) clone number and protein name: LP2254
Start code: 640 ATG stop coding: 1327 TAA protein molecular weights: 25646.89
5.LP2261
A: nucleotide sequence (SEQ ID NO:13) length: 1309 bases
B: aminoacid sequence (SEQ ID NO:15) length: 314 amino acid
C. Nucleotide and amino acid composite sequence (SEQ ID NO:14) clone number and protein name: LP2261
Start code: 35 ATG stop coding: 977 TAA protein molecular weights: 33765.42
6.LP2477
A: nucleotide sequence (SEQ ID NO:16) length: 1708 bases
B: aminoacid sequence (SEQ ID NO:18) length: 125 amino acid
C. Nucleotide and amino acid composite sequence (SEQ ID NO:17) clone number and protein name: LP2477
Start code: 523 ATG stop coding: 898 TAA protein molecular weights: 13538.77
7.LP2537
A: nucleotide sequence (SEQ ID NO:19) length: 1191 bases
B: aminoacid sequence (SEQ ID NO:21) length: 279 amino acid
C. Nucleotide and amino acid composite sequence (SEQ ID NO:20) clone number and protein name: LP2537
Start code: 77 ATG stop coding: 914 TGA protein molecular weights: 31629.09
8.LP2561
A: nucleotide sequence (SEQ ID NO:22) length: 1493 bases
B: aminoacid sequence (SEQ ID NO:24) length: 317 amino acid
C. Nucleotide and amino acid composite sequence (SEQ ID NO:23) clone number and protein name: LP2561
Start code: 390 ATG stop coding: 1341 TAG protein molecular weights: 32576.68
9.LP2642
A: nucleotide sequence (SEQ ID NO:25) length: 1284 bases
B: aminoacid sequence (SEQ ID NO:27) length: 224 amino acid
C. Nucleotide and amino acid composite sequence (SEQ ID NO:26) clone number and protein name: LP2642
Start code: 54 ATG stop coding: 726 TGA protein molecular weights: 25970.40
10.LP2698
A: nucleotide sequence (SEQ ID NO:28) length: 1299 bases
B: aminoacid sequence (SEQ ID NO:30) length: 253 amino acid
C. Nucleotide and amino acid composite sequence (SEQ ID NO:29) clone number and protein name: LP2698
Start code: 339 ATG stop coding: 1098 TAA protein molecular weights: 27953.79
11.LP2709
A: nucleotide sequence (SEQ ID NO:31) length: 1237 bases
B: aminoacid sequence (SEQ ID NO:33) length: 212 amino acid
C. Nucleotide and amino acid composite sequence (SEQ ID NO:32) clone number and protein name: LP2709
Start code: 353 ATG stop coding: 989 TAG protein molecular weights: 22099.74
12.LP3663
A: nucleotide sequence (SEQ ID NO:34) length: 1320 bases
B: aminoacid sequence (SEQ ID NO:36) length: 184 amino acid
C. Nucleotide and amino acid composite sequence (SEQ ID NO:35) clone number and protein name: LP3663
Start code: 459 ATG stop coding: 1011 TGA protein molecular weights: 21098.00
13.LP3727
A: nucleotide sequence (SEQ ID NO:37) length: 1205 bases
B: aminoacid sequence (SEQ ID NO:39) length: 198 amino acid
C. Nucleotide and amino acid composite sequence (SEQ ID NO:38) clone number and protein name: LP3727
Start code: 181 ATG stop coding: 775 TGA protein molecular weights: 21481.24
All quote in this application as a reference at all documents that the present invention mentions, just quoted as a reference separately as each piece document.Should be understood that in addition those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims institute restricted portion equally.
Sequence table
＜110〉Shanghai Xinshijie Gene Techn Development Co., Ltd.
＜120〉have new the people's albumen and the encoding sequence thereof of promotion mouse NIH/3T3 cell transformation function
<130>024918
<160>65
<170>PatentIn version 3.1
<210>1
<211>2748
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<400>1
gcctcagtcg gccccctggc ttcaagatac atcaaggtcc ctgctacccg agccaaggac 60
acctctccca cagtgcttcc ccaccctgct cccaacaaga ctccttctca cgggtggtct 120
tgcacagctg gagcccatag tgcagcaggt gctggctgaa gagcccctgg ctccacactg 180
ccccactcct gaccagggtg atgcactgga ggagggcttg gaccctcagc tcctccctca 240
gtgctcccga ccacttccag ggactatccc caagctggcc agcactcctg cgccccaaga 300
ggagtgtttg gggtgcttcc tcttggctgc agtgggacac aggtgtgcct tcctaggaac 360
tgggccctga ctacttccag cccaacactc ccgggcctgt gaactgtgac ctgtgtgccg 420
ggatgggttt tgtgggtctg ccccatcccc gcactgctgg atctggccaa gtgggtgaag 480
gctaaggccg gtcagagttg agtttctgcc ttgtcccctc tcctgggcta gatgccacac 540
caggcccagt gactcatagg gcaggcagtt gggaaatacc aggcagaggg caggtcctgg 600
tctcagctgg ccagcctctg ctgtctgcca tcccagggga ggtggccaaa gtcccaactg 660
tgagccaggc cccacattca ctgggcctcc tccagggtct gtatgccatg gaaccctgga 720
catggggcta tgaaggaagg tgggtgttgc taagcccagg agcatgggcc cctaaccttg 780
gccctgtgcc ccaggtgagg ctggtgccaa gttcattgag gtatctaaag aggcccggaa 840
gcggttcctg ggccccctgc acccctcctt caacctggta aagatcatcc gcagtttcct 900
gctgaaggtc ctgcctgctg atagccatga gcatgccagt gggcgcctgg gcatctccct 960
gacccgcgtg tcagacggcg agaatgtcat tatatcccac ttcaactcca aggacgagct 1020
catccaggcc aatgtctgca gcggtttcat ccccgtgtac tgtgggctca tccctccctc 1080
cctccagggg gtgcgctacg tggatggtgg catttcagac aacctgccac tctatgagct 1140
taagaacacc atcacagtgt cccccttctc gggcgagagt gacatctgtc cgcaggacag 1200
ctccaccaac atccacgagc tgcgggtcac caacaccagc atccagttca acctgcgcaa 1260
cctctaccgc ctctccaagg ccctcttccc gccggagccc ctggtgctgc gagagatgtg 1320
caagcaggga taccgggatg gcctgcgctt tctgcagcgg aacggtgcgc ggacccgggc 1380
gggagagggc ggggtgggct cggctctgct accccctgcg ggccgcggcc gcgctgatga 1440
actgagaatc ccttctctcc ccaaccccag gcctcctgaa ccggcccaac cccttgctgg 1500
cgttgccccc cgcccgcccc cacggcccag aggacaagga ccaggcagtg gagagcgccc 1560
aagcggagga ttactcgcag ctgccgggag aagatcacat cctggagcac ctgcccgccc 1620
ggctcaatga gggtgcgcac ctgggggacg ggaggggagg aggggaggca ggagggaaag 1680
agagagagga gaggacggtg agcaggggag ggaagccgag cggtcctggg cccccgtgcc 1740
tccactggcc gccgacctcc cgcccacccg cagccctgct ggaggcctgc gtggagccca 1800
cggacctgct gaccaccctc tccaacatgc tgcctgtgcg tctggccaca ggctgatggt 1860
gccctacacg ctgccgctgg agagcgctct gtccttcacc atccgcttgc tggagtggct 1920
gcccgacgtt cccgaggaca tccggtggat gaaggagcag acgggcagca tctgccagta 1980
cctggtgatg cgcgccaaga ggaagctggg caggcacctg ccctccaggc tgccggagca 2040
ggtggagctg cgccgcgtcc agtcgctgcc gtccgtgccg ctgtcctgcg ccgcctacag 2100
agaggcactg cccggctgga tgcgcaacaa cctctcgctg ggggacgcgc tggccaagtg 2160
ggaggagtgc cagcgccagc tgctgctcgg cctcttctgc accaacgtgg ccttcccgcc 2220
cgaagctctg cgcatgcgcg cacccgccga cccggctccc gcccccgcgg acccagcatc 2280
cccgcagcac cagctggccg ggcctgcccc cttgctgagc acccctgctc ccgaggcccg 2340
gcccgtgatc ggggcccctg gggctgtgag accccgaccc tctcgaggaa ccctgcctga 2400
gacgcctcca ttaccactgc gcagtgagat gaggggactc acagttgcca agaggggtct 2460
ttgccgtggg ccccctcgcc agccactcac cagctgcatg cactgagagg ggaggtttcc 2520
acacccctcc cctgggccgc tgaggccccg cgcacctgtg ccttaatctt ccctcccctg 2580
tgctgcccga gcacctcccc cgccccttta ctcctgagaa ctttgcagct gcccttccct 2640
ccccgttttt catggcctgc tgaaatatgt gtgtgaagaa ttatttattt tcgccaaagc 2700
acatgtaata aatgctgcag cccagcaaaa aaaaaaaaaa aaaaaaaa 2748
<210>2
<211>2748
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<220>
<221>CDS
<222>(1856)..(2503)
<223>
<400>2
gcctcagtcg gccccctggc ttcaagatac atcaaggtcc ctgctacccg agccaaggac 60
acctctccca cagtgcttcc ccaccctgct cccaacaaga ctccttctca cgggtggtct 120
tgcacagctg gagcccatag tgcagcaggt gctggctgaa gagcccctgg ctccacactg 180
ccccactcct gaccagggtg atgcactgga ggagggcttg gaccctcagc tcctccctca 240
gtgctcccga ccacttccag ggactatccc caagctggcc agcactcctg cgccccaaga 300
ggagtgtttg gggtgcttcc tcttggctgc agtgggacac aggtgtgcct tcctaggaac 360
tgggccctga ctacttccag cccaacactc ccgggcctgt gaactgtgac ctgtgtgccg 420
ggatgggttt tgtgggtctg ccccatcccc gcactgctgg atctggccaa gtgggtgaag 480
gctaaggccg gtcagagttg agtttctgcc ttgtcccctc tcctgggcta gatgccacac 540
caggcccagt gactcatagg gcaggcagtt gggaaatacc aggcagaggg caggtcctgg 600
tctcagctgg ccagcctctg ctgtctgcca tcccagggga ggtggccaaa gtcccaactg 660
tgagccaggc cccacattca ctgggcctcc tccagggtct gtatgccatg gaaccctgga 720
catggggcta tgaaggaagg tgggtgttgc taagcccagg agcatgggcc cctaaccttg 780
gccctgtgcc ccaggtgagg ctggtgccaa gttcattgag gtatctaaag aggcccggaa 840
gcggttcctg ggccccctgc acccctcctt caacctggta aagatcatcc gcagtttcct 900
gctgaaggtc ctgcctgctg atagccatga gcatgccagt gggcgcctgg gcatctccct 960
gacccgcgtg tcagacggcg agaatgtcat tatatcccac ttcaactcca aggacgagct 1020
catccaggcc aatgtctgca gcggtttcat ccccgtgtac tgtgggctca tccctccctc 1080
cctccagggg gtgcgctacg tggatggtgg catttcagac aacctgccac tctatgagct 1140
taagaacacc atcacagtgt cccccttctc gggcgagagt gacatctgtc cgcaggacag 1200
ctccaccaac atccacgagc tgcgggtcac caacaccagc atccagttca acctgcgcaa 1260
cctctaccgc ctctccaagg ccctcttccc gccggagccc ctggtgctgc gagagatgtg 1320
caagcaggga taccgggatg gcctgcgctt tctgcagcgg aacggtgcgc ggacccgggc 1380
gggagagggc ggggtgggct cggctctgct accccctgcg ggccgcggcc gcgctgatga 1440
actgagaatc ccttctctcc ccaaccccag gcctcctgaa ccggcccaac cccttgctgg 1500
cgttgccccc cgcccgcccc cacggcccag aggacaagga ccaggcagtg gagagcgccc 1560
aagcggagga ttactcgcag ctgccgggag aagatcacat cctggagcac ctgcccgccc 1620
ggctcaatga gggtgcgcac ctgggggacg ggaggggagg aggggaggca ggagggaaag 1680
agagagagga gaggacggtg agcaggggag ggaagccgag cggtcctggg cccccgtgcc 1740
tccactggcc gccgacctcc cgcccacccg cagccctgct ggaggcctgc gtggagccca 1800
cggacctgct gaccaccctc tccaacatgc tgcctgtgcg tctggccaca ggctg atg 1858
Met
1
gtg ccc tac acg ctg ccg ctg gag agc gct ctg tcc ttc acc atc cgc 1906
Val Pro Tyr Thr Leu Pro Leu Glu Ser Ala Leu Ser Phe Thr Ile Arg
5 10 15
ttg ctg gag tgg ctg ccc gac gtt ccc gag gac atc cgg tgg atg aag 1954
Leu Leu Glu Trp Leu Pro Asp Val Pro Glu Asp Ile Arg Trp Met Lys
20 25 30
gag cag acg ggc agc atc tgc cag tac ctg gtg atg cgc gcc aag agg 2002
Glu Gln Thr Gly Ser Ile Cys Gln Tyr Leu Val Met Arg Ala Lys Arg
35 40 45
aag ctg ggc agg cac ctg ccc tcc agg ctg ccg gag cag gtg gag ctg 2050
Lys Leu Gly Arg His Leu Pro Ser Arg Leu Pro Glu Gln Val Glu Leu
50 55 60 65
cgc cgc gtc cag tcg ctg ccg tcc gtg ccg ctg tcc tgc gcc gcc tac 2098
Arg Arg Val Gln Ser Leu Pro Ser Val Pro Leu Ser Cys Ala Ala Tyr
70 75 80
aga gag gca ctg ccc ggc tgg atg cgc aac aac ctc tcg ctg ggg gac 2146
Arg Glu Ala Leu Pro Gly Trp Met Arg Asn Asn Leu Ser Leu Gly Asp
85 90 95
gcg ctg gcc aag tgg gag gag tgc cag cgc cag ctg ctg ctc ggc ctc 2194
Ala Leu Ala Lys Trp Glu Glu Cys Gln Arg Gln Leu Leu Leu Gly Leu
100 105 110
ttc tgc acc aac gtg gcc ttc ccg ccc gaa gct ctg cgc atg cgc gca 2242
Phe Cys Thr Asn Val Ala Phe Pro Pro Glu Ala Leu Arg Met Arg Ala
115 120 125
ccc gcc gac ccg gct ccc gcc ccc gcg gac cca gca tcc ccg cag cac 2290
Pro Ala Asp Pro Ala Pro Ala Pro Ala Asp Pro Ala Ser Pro Gln His
130 135 140 145
cag ctg gcc ggg cct gcc ccc ttg ctg agc acc cct gct ccc gag gcc 2338
Gln Leu Ala Gly Pro Ala Pro Leu Leu Ser Thr Pro Ala Pro Glu Ala
150 155 160
cgg ccc gtg atc ggg gcc cct ggg gct gtg aga ccc cga ccc tct cga 2386
Arg Pro Val Ile Gly Ala Pro Gly Ala Val Arg Pro Arg Pro Ser Arg
165 170 175
gga acc ctg cct gag acg cct cca tta cca ctg cgc agt gag atg agg 2434
Gly Thr Leu Pro Glu Thr Pro Pro Leu Pro Leu Arg Ser Glu Met Arg
180 185 190
gga ctc aca gtt gcc aag agg ggt ctt tgc cgt ggg ccc cct cgc cag 2482
Gly Leu Thr Val Ala Lys Arg Gly Leu Cys Arg Gly Pro Pro Arg Gln
195 200 205
cca ctc acc agc tgc atg cac tgagagggga ggtttccaca cccctcccct 2533
Pro Leu Thr Ser Cys Met His
210 215
gggccgctga ggccccgcgc acctgtgcct taatcttccc tcccctgtgc tgcccgagca 2593
cctcccccgc ccctttactc ctgagaactt tgcagctgcc cttccctccc cgtttttcat 2653
ggcctgctga aatatgtgtg tgaagaatta tttattttcg ccaaagcaca tgtaataaat 2713
gctgcagccc agcaaaaaaa aaaaaaaaaa aaaaa 2748
<210>3
<211>216
<212>PRT
＜213〉homo sapiens (Homo sapiens)
<400>3
Met Val Pro Tyr Thr Leu Pro Leu Glu Ser Ala Leu Ser Phe Thr Ile
1 5 10 15
Arg Leu Leu Glu Trp Leu Pro Asp Val Pro Glu Asp Ile Arg Trp Met
20 25 30
Lys Glu Gln Thr Gly Ser Ile Cys Gln Tyr Leu Val Met Arg Ala Lys
35 40 45
Arg Lys Leu Gly Arg His Leu Pro Ser Arg Leu Pro Glu Gln Val Glu
50 55 60
Leu Arg Arg Val Gln Ser Leu Pro Ser Val Pro Leu Ser Cys Ala Ala
65 70 75 80
Tyr Arg Glu Ala Leu Pro Gly Trp Met Arg Asn Asn Leu Ser Leu Gly
85 90 95
Asp Ala Leu Ala Lys Trp Glu Glu Cys Gln Arg Gln Leu Leu Leu Gly
100 105 110
Leu Phe Cys Thr Asn Val Ala Phe Pro Pro Glu Ala Leu Arg Met Arg
115 120 125
Ala Pro Ala Asp Pro Ala Pro Ala Pro Ala Asp Pro Ala Ser Pro Gln
130 135 140
His Gln Leu Ala Gly Pro Ala Pro Leu Leu Ser Thr Pro Ala Pro Glu
145 150 155 160
Ala Arg Pro Val Ile Gly Ala Pro Gly Ala Val Arg Pro Arg Pro Ser
165 170 175
Arg Gly Thr Leu Pro Glu Thr Pro Pro Leu Pro Leu Arg Ser Glu Met
180 185 190
Arg Gly Leu Thr Val Ala Lys Arg Gly Leu Cys Arg Gly Pro Pro Arg
195 200 205
Gln Pro Leu Thr Ser Cys Met His
210 215
<210>4
<211>2070
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<400>4
gccgcacaca tgtgtagtca catgcgcatc cacatacaca taacagaagc cagtgtcctt 60
caccatgcag ccaggcactc cggcagtttc tgctctattt tattttacaa aattgctggg 120
ggtgactcat gaaactgatt tcaaaatgca catttgaaaa gcatggtcct agctggcacc 180
ccctggtggc agcccgggcc tcgggtgtgg gtccaggtgg gatccccccc atccccaact 240
ctgggttctg agctgggata aaggcctctt ggcggtgttg ctgggggcca cagccccaac 300
agcgcccttc ctgctctccc ccaccggcca cagagcgtga gtcccgacca ccgcgtccgc 360
cggcgcccct cagtgggcct ttgtcccaag aagctgccaa gccaggtggg gactgctctc 420
accgcccgtg tggcaggctg tcctctgaag gacagagtcc tcttctctcg tgtccctaag 480
cctagcaggc agtgggaatg aacgggcagc ccggttgctg ggcacccatc tccccagcct 540
agccggtgtg tggaggattg cagcccttta gcccagcctg cccaggcaag cctgccgggg 600
tgagcaggag ggcttctggg gtgaagggag gtgggggagg gagggagacc acgggcggag 660
gctcacctga actgaatgca ggaggggcag tgcctttgca ccagaaagag cccatgtgtc 720
cttctcacca tcccctgtgc ttacaccccc agtcagcatg ctccgggggt ccctgagccg 780
ggccgcccca gacggccctc cttccctccc acccaccacc ccgcgacccc tcccaaacgt 840
gtgcgccagg aagatgactc cagggtgcct ttagctgggg ctgtagtggt tgggacgggc 900
ggctgtatat caggggtgag ttccagggag acttgggggc ttagaaaact tagaaaactt 960
ctccaagttg ggagagaatc ccgcccgccc tgccggaggc ggggctcagt gccctgaagt 1020
ggaggcgccc gtgggccacc tccctccctg cagccgcagc cgctgcgcag aggcgctggc 1080
tccttctcct cccacctggg acaggtgtct ccccagcccc cgctcccagg ggcctctctc 1140
tctctcccgc cccgcagggt cgagtcccgg caggggctcg gggatcgggt agtcagtacc 1200
tctctgcgtc tccagccgcc ggtagttggg gaccctgtgg ctggagtgcg ttttcaccag 1260
gaaggagcgc ggcatgttcc cctcccgggc ggcaggccgg ggtgggctgg ggcggggagg 1320
gcgcgcctgg gtccggactg ctgcgtccgc cggcgcttga aggggtcagg ctcattagca 1380
tagcgcgccg cctccgccaa ccagcgcccg gcgcgagtgg ggcggggcca cgggggcgga 1440
actgagggcg aggcggggtc tcgggcaaca cgcccaggac aggtgcgcgg gcgggacggg 1500
gcggggagcg cgtggccgcc cggtgtcctc cccacgggaa ttctctggcg tgcgcgccgc 1560
cgagtcacac accgacccgt cgggcctggc cacccactcg ccgtgagtga agggcagagt 1620
tcaaagctgt gtggaaaccg agcgagaatc tcttccacag aatgtggaag cgtcggccga 1680
gcgcggtcct tggagaaccc ttgctgcgga gaatgacgct cactctgcgg cctggcctcg 1740
cctccccatc ccttctgcaa actcacagga caggattgat ggggagagcc caggcgaaac 1800
gaagctgacc ctagtgacca gccctactgg cggctctgga acaggcccgg gaccggtggc 1860
ctggagacag tggtcctttc tggatgggct gcagtctccg aaggcttccc ccactggagt 1920
cagcccttta ggagtttgtc cagtgcctcc agaaaactgt tttttggggg acggaggact 1980
tggcctggaa ttctggaatt cccagggggt cagacatggt tatgggaagt ttaataaaac 2040
cggtgaatca aaaaaaaaaa aaaaaaaaag 2070
<210>5
<211>2070
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<220>
<221>CDS
<222>(676)..(1014)
<223>
<400>5
gccgcacaca tgtgtagtca catgcgcatc cacatacaca taacagaagc cagtgtcctt 60
caccatgcag ccaggcactc cggcagtttc tgctctattt tattttacaa aattgctggg 120
ggtgactcat gaaactgatt tcaaaatgca catttgaaaa gcatggtcct agctggcacc 180
ccctggtggc agcccgggcc tcgggtgtgg gtccaggtgg gatccccccc atccccaact 240
ctgggttctg agctgggata aaggcctctt ggcggtgttg ctgggggcca cagccccaac 300
agcgcccttc ctgctctccc ccaccggcca cagagcgtga gtcccgacca ccgcgtccgc 360
cggcgcccct cagtgggcct ttgtcccaag aagctgccaa gccaggtggg gactgctctc 420
accgcccgtg tggcaggctg tcctctgaag gacagagtcc tcttctctcg tgtccctaag 480
cctagcaggc agtgggaatg aacgggcagc ccggttgctg ggcacccatc tccccagcct 540
agccggtgtg tggaggattg cagcccttta gcccagcctg cccaggcaag cctgccgggg 600
tgagcaggag ggcttctggg gtgaagggag gtgggggagg gagggagacc acgggcggag 660
gctcacctga actga atg cag gag ggg cag tgc ctt tgc acc aga aag agc 711
Met Gln Glu Gly Gln Cys Leu Cys Thr Arg Lys Ser
1 5 10
cca tgt gtc ctt ctc acc atc ccc tgt gct tac acc ccc agt cag cat 759
Pro Cys Val Leu Leu Thr Ile Pro Cys Ala Tyr Thr Pro Ser Gln His
15 20 25
gct ccg ggg gtc cct gag ccg ggc cgc ccc aga cgg ccc tcc ttc cct 807
Ala Pro Gly Val Pro Glu Pro Gly Arg Pro Arg Arg Pro Ser Phe Pro
30 35 40
ccc acc cac cac ccc gcg acc cct ccc aaa cgt gtg cgc cag gaa gat 855
Pro Thr His His Pro Ala Thr Pro Pro Lys Arg Val Arg Gln Glu Asp
45 50 55 60
gac tcc agg gtg cct tta gct ggg gct gta gtg gtt ggg acg ggc ggc 903
Asp Ser Arg Val Pro Leu Ala Gly Ala Val Val Val Gly Thr Gly Gly
65 70 75
tgt ata tca ggg gtg agt tcc agg gag act tgg ggg ctt aga aaa ctt 951
Cys Ile Ser Gly Val Ser Ser Arg Glu Thr Trp Gly Leu Arg Lys Leu
80 85 90
aga aaa ctt ctc caa gtt ggg aga gaa tcc cgc ccg ccc tgc cgg agg 999
Arg Lys Leu Leu Gln Val Gly Arg Glu Ser Arg Pro Pro Cys Arg Arg
95 100 105
cgg ggc tca gtg ccc tgaagtggag gcgcccgtgg gccacctccc tccctgcagc 1054
Arg Gly Ser Val Pro
110
cgcagccgct gcgcagaggc gctggctcct tctcctccca cctgggacag gtgtctcccc 1114
agcccccgct cccaggggcc tctctctctc tcccgccccg cagggtcgag tcccggcagg 1174
ggctcgggga tcgggtagtc agtacctctc tgcgtctcca gccgccggta gttggggacc 1234
ctgtggctgg agtgcgtttt caccaggaag gagcgcggca tgttcccctc ccgggcggca 1294
ggccggggtg ggctggggcg gggagggcgc gcctgggtcc ggactgctgc gtccgccggc 1354
gcttgaaggg gtcaggctca ttagcatagc gcgccgcctc cgccaaccag cgcccggcgc 1414
gagtggggcg gggccacggg ggcggaactg agggcgaggc ggggtctcgg gcaacacgcc 1474
caggacaggt gcgcgggcgg gacggggcgg ggagcgcgtg gccgcccggt gtcctcccca 1534
cgggaattct ctggcgtgcg cgccgccgag tcacacaccg acccgtcggg cctggccacc 1594
cactcgccgt gagtgaaggg cagagttcaa agctgtgtgg aaaccgagcg agaatctctt 1654
ccacagaatg tggaagcgtc ggccgagcgc ggtccttgga gaacccttgc tgcggagaat 1714
gacgctcact ctgcggcctg gcctcgcctc cccatccctt ctgcaaactc acaggacagg 1774
attgatgggg agagcccagg cgaaacgaag ctgaccctag tgaccagccc tactggcggc 1834
tctggaacag gcccgggacc ggtggcctgg agacagtggt cctttctgga tgggctgcag 1894
tctccgaagg cttcccccac tggagtcagc cctttaggag tttgtccagt gcctccagaa 1954
aactgttttt tgggggacgg aggacttggc ctggaattct ggaattccca gggggtcaga 2014
catggttatg ggaagtttaa taaaaccggt gaatcaaaaa aaaaaaaaaa aaaaag 2070
<210>6
<211>113
<212>PRT
＜213〉homo sapiens (Homo sapiens)
<400>6
Met Gln Glu Gly Gln Cys Leu Cys Thr Arg Lys Ser Pro Cys Val Leu
1 5 10 15
Leu Thr Ile Pro Cys Ala Tyr Thr Pro Ser Gln His Ala Pro Gly Val
20 25 30
Pro Glu Pro Gly Arg Pro Arg Arg Pro Ser Phe Pro Pro Thr His His
35 40 45
Pro Ala Thr Pro Pro Lys Arg Val Arg Gln Glu Asp Asp Ser Arg Val
50 55 60
Pro Leu Ala Gly Ala Val Val Val Gly Thr Gly Gly Cys Ile Ser Gly
65 70 75 80
Val Ser Ser Arg Glu Thr Trp Gly Leu Arg Lys Leu Arg Lys Leu Leu
85 90 95
Gln Val Gly Arg Glu Ser Arg Pro Pro Cys Arg Arg Arg Gly Ser Val
100 105 110
Pro
<210>7
<211>2392
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<400>7
gaacattttc atcttccagt tgcagctggc gtggggctct cgcctgtaat cccagtactt 60
aagaggctga tgggggagaa gcactgtagg ccaggagttc aagaccagcc tgggcaacat 120
agtgagaccc cccccccatc tctacaaaaa ataaaaaaat cttcccgttg ctgtatgtgg 180
agcccctcta gattgtcagt gatagaaacc acttcaaact ggctcagccc taaaatagcg 240
atgattttgt ggctcacgta actgaggatt ccaatgggca cagctggttg caggccccgc 300
tggacccagc tctctgctgg ccccaggcca cttgctggca gcttcccacc cactgtcaga 360
gcctgtcccc ccggtggtgg tctcacacca tcttcacccc tcaactccag gggtgacgct 420
tcctggccca cctgggctcc tgcgccttcc ctgaaccacc ctcggtgacc agggtgggtg 480
accagacctg gaggtggggt tgccctgctg gagccctgtg ggaggagggg agaaggtggc 540
tcccgtgctg ggtgggcagg gggcgcgtct tgtggagtcc agctctgtcc tggcatcggt 600
ccctgcccca cacagcctta aaattccttc ccaccctcaa agcccagctt gggtgtcctc 660
gggggccttt ctcccgcctt ccatggggct tcctgctctg ccgcaggtac cttttgttgc 720
ccttgtcgca ggccgcaagc tctgcaggcc gtgaacagag agtgtccgag agtggaacta 780
gcggaggtgg gggacagacg gctgggccgg tgaatgctgg cctcaaaggc tgatggccca 840
gaagccctgt catctggaaa tccccatttg ccgtggggtg tgggacgttc ctggggcggt 900
gagctgtcag ggagcacagc gcaggcagct ctgaggaccc tccctgaatc cgcatgcctg 960
cagcctacac cctggcccgt gtctacggcg tggagagtga cctctcagaa gtggctcgcc 1020
ggggctcagg cagcgcctgc cggagcctgt atgggggctt tgtggagtgc agatgggaga 1080
gcaggccgac gggaaggaca gcatcgctcg gcaagtggcc cccgagtcac actggcctga 1140
actccgcgtg ctcatccttg tggtgagcgc tgagaagaag ctgacaggca gtaccgtggg 1200
catgcgggcc agtgtggaga ccagccccct gcttcggttc cgggccgagt ccgtggtgcc 1260
ccgcgcgcat ggcggagatg gcccgctgca tccgggagcg agacttcccc agcttcgccc 1320
agctgaccat gaaggacagc aaccagttcc acgccacctg cctcgacacc ttccccgccc 1380
atctcttacc tcaatgccat ctcctggcgc atcatccacc tggtgcaccg cttcaacgcc 1440
caccacgggg acaccaaggt ggcgtacacc tttgacgcgg gccccaatgc cgtgatcttc 1500
accctggacg acactgtggc tgagtttgtg gctgctgtgt ggcacggctt tcccccaggc 1560
tcgaatggag acacgtttct gaaggggctg caggtgaggc cggcccctct ctcagctgag 1620
cttcaggctg cgctggccat ggagcgaccc ccggtggggt caaatacatc attgtcactc 1680
aggtggggcc agggcctcaa atcctggatg acccctgcgc ccacctcctg ggtcctgacg 1740
gcctgccgaa gccagctgcc tgactgcctc agcagggacc gcatgccgct tggagaaggg 1800
gtggcctcgc cggagctagg gagcggatgt ggtgggctgg ccggactcct gggacatgtg 1860
ggtggtggct tgaccccggg cccatgggca gcttgctgtg gggcagtgca gggagtcctg 1920
cggccgccca ggtgtcagga gaggtccccg ccgagtgctt cagctgccct aagctgcacc 1980
agcgctttgc caagatggga tggggagggg gtatgagaac tggcagagcc tcggtgcagc 2040
agggctgaag ggctttctca ccccagctct ggctatgcca gttctctgag aaaggagctc 2100
agtggggagg tggtccctcc agcggaccag ggaaggggtc actgtgctgg gagcagcctc 2160
cttgggcctc aggaaaccac caagtgcctc ggatggtggc tgcccacgcg cgcttctgct 2220
gagaccctgc ccccggccca ggtgtctcgg agggtggctg cccacggcct gggtgtggct 2280
ggaatggtgg caggagtggg caccagtgcg gccccggtgg ccatggggaa taaaccagca 2340
ttgctgcctc cggaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa at 2392
<210>8
<211>2392
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<220>
<221>CDS
<222>(1073)..(1492)
<223>
<400>8
gaacattttc atcttccagt tgcagctggc gtggggctct cgcctgtaat cccagtactt 60
aagaggctga tgggggagaa gcactgtagg ccaggagttc aagaccagcc tgggcaacat 120
agtgagaccc cccccccatc tctacaaaaa ataaaaaaat cttcccgttg ctgtatgtgg 180
agcccctcta gattgtcagt gatagaaacc acttcaaact ggctcagccc taaaatagcg 240
atgattttgt ggctcacgta actgaggatt ccaatgggca cagctggttg caggccccgc 300
tggacccagc tctctgctgg ccccaggcca cttgctggca gcttcccacc cactgtcaga 360
gcctgtcccc ccggtggtgg tctcacacca tcttcacccc tcaactccag gggtgacgct 420
tcctggccca cctgggctcc tgcgccttcc ctgaaccacc ctcggtgacc agggtgggtg 480
accagacctg gaggtggggt tgccctgctg gagccctgtg ggaggagggg agaaggtggc 540
tcccgtgctg ggtgggcagg gggcgcgtct tgtggagtcc agctctgtcc tggcatcggt 600
ccctgcccca cacagcctta aaattccttc ccaccctcaa agcccagctt gggtgtcctc 660
gggggccttt ctcccgcctt ccatggggct tcctgctctg ccgcaggtac cttttgttgc 720
ccttgtcgca ggccgcaagc tctgcaggcc gtgaacagag agtgtccgag agtggaacta 780
gcggaggtgg gggacagacg gctgggccgg tgaatgctgg cctcaaaggc tgatggccca 840
gaagccctgt catctggaaa tccccatttg ccgtggggtg tgggacgttc ctggggcggt 900
gagctgtcag ggagcacagc gcaggcagct ctgaggaccc tccctgaatc cgcatgcctg 960
cagcctacac cctggcccgt gtctacggcg tggagagtga cctctcagaa gtggctcgcc 1020
ggggctcagg cagcgcctgc cggagcctgt atgggggctt tgtggagtgc ag atg gga 1078
Met Gly
1
gag cag gcc gac ggg aag gac agc atc gct cgg caa gtg gcc ccc gag 1126
Glu Gln Ala Asp Gly Lys Asp Ser Ile Ala Arg Gln Val Ala Pro Glu
5 10 15
tca cac tgg cct gaa ctc cgc gtg ctc atc ctt gtg gtg agc gct gag 1174
Ser His Trp Pro Glu Leu Arg Val Leu Ile Leu Val Val Ser Ala Glu
20 25 30
aag aag ctg aca ggc agt acc gtg ggc atg cgg gcc agt gtg gag acc 1222
Lys Lys Leu Thr Gly Ser Thr Val Gly Met Arg Ala Ser Val Glu Thr
35 40 45 50
agc ccc ctg ctt cgg ttc cgg gcc gag tcc gtg gtg ccc cgc gcg cat 1270
Ser Pro Leu Leu Arg Phe Arg Ala Glu Ser Val Val Pro Arg Ala His
55 60 65
ggc gga gat ggc ccg ctg cat ccg gga gcg aga ctt ccc cag ctt cgc 1318
Gly Gly Asp Gly Pro Leu His Pro Gly Ala Arg Leu Pro Gln Leu Arg
70 75 80
cca gct gac cat gaa gga cag caa cca gtt cca cgc cac ctg cct cga 1366
Pro Ala Asp His Glu Gly Gln Gln Pro Val Pro Arg His Leu Pro Arg
85 90 95
cac ctt ccc cgc cca tct ctt acc tca atg cca tct cct ggc gca tca 1414
His Leu Pro Arg Pro Ser Leu Thr Ser Met Pro Ser Pro Gly Ala Ser
100 105 110
tcc acc tgg tgc acc gct tca acg ccc acc acg ggg aca cca agg tgg 1462
Ser Thr Trp Cys Thr Ala Ser Thr Pro Thr Thr Gly Thr Pro Arg Trp
115 120 125 130
cgt aca cct ttg acg cgg gcc cca atg ccg tgatcttcac cctggacgac 1512
Arg Thr Pro Leu Thr Arg Ala Pro Met Pro
135 140
actgtggctg agtttgtggc tgctgtgtgg cacggctttc ccccaggctc gaatggagac 1572
acgtttctga aggggctgca ggtgaggccg gcccctctct cagctgagct tcaggctgcg 1632
ctggccatgg agcgaccccc ggtggggtca aatacatcat tgtcactcag gtggggccag 1692
ggcctcaaat cctggatgac ccctgcgccc acctcctggg tcctgacggc ctgccgaagc 1752
cagctgcctg actgcctcag cagggaccgc atgccgcttg gagaaggggt ggcctcgccg 1812
gagctaggga gcggatgtgg tgggctggcc ggactcctgg gacatgtggg tggtggcttg 1872
accccgggcc catgggcagc ttgctgtggg gcagtgcagg gagtcctgcg gccgcccagg 1932
tgtcaggaga ggtccccgcc gagtgcttca gctgccctaa gctgcaccag cgctttgcca 1992
agatgggatg gggagggggt atgagaactg gcagagcctc ggtgcagcag ggctgaaggg 2052
ctttctcacc ccagctctgg ctatgccagt tctctgagaa aggagctcag tggggaggtg 2112
gtccctccag cggaccaggg aaggggtcac tgtgctggga gcagcctcct tgggcctcag 2172
gaaaccacca agtgcctcgg atggtggctg cccacgcgcg cttctgctga gaccctgccc 2232
ccggcccagg tgtctcggag ggtggctgcc cacggcctgg gtgtggctgg aatggtggca 2292
ggagtgggca ccagtgcggc cccggtggcc atggggaata aaccagcatt gctgcctccg 2352
gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaat 2392
<210>9
<211>140
<212>PRT
＜213〉homo sapiens (Homo sapiens)
<400>9
Met Gly Glu Gln Ala Asp Gly Lys Asp Ser Ile Ala Arg Gln Val Ala
1 5 10 15
Pro Glu Ser His Trp Pro Glu Leu Arg Val Leu Ile Leu Val Val Ser
20 25 30
Ala Glu Lys Lys Leu Thr Gly Ser Thr Val Gly Met Arg Ala Ser Val
35 40 45
Glu Thr Ser Pro Leu Leu Arg Phe Arg Ala Glu Ser Val Val Pro Arg
50 55 60
Ala His Gly Gly Asp Gly Pro Leu His Pro Gly Ala Arg Leu Pro Gln
65 70 75 80
Leu Arg Pro Ala Asp His Glu Gly Gln Gln Pro Val Pro Arg His Leu
85 90 95
Pro Arg His Leu Pro Arg Pro Ser Leu Thr Ser Met Pro Ser Pro Gly
100 105 110
Ala Ser Ser Thr Trp Cys Thr Ala Ser Thr Pro Thr Thr Gly Thr Pro
115 120 125
Arg Trp Arg Thr Pro Leu Thr Arg Ala Pro Met Pro
130 135 140
<210>10
<211>1551
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<400>10
ggtcacctgt gttaggctcc gtcccctttc cgcgttttat ccccgtacca gaaaaggata 60
catttagtgc ctcccaccca gctccactaa acgggttgga tatctcattc tttgagttgg 120
tgttccttcc ccggcgcccc catgtagctg ggaagtggga cctgggggtg gttggacccc 180
tgggatccta aaggaggggc agggagggcg cagaactccg cttctgctcc ttgctaccag 240
gacgcgcggc ctcctcagcc tctttcctcc cgctgccatg caccctgcag ccttcccgct 300
tcctgtggtt gtggccgctg tgctgtgggg agcggccccg acccgggggc tcattcgagc 360
gacctcggac cacaatgcca gcatggactt tgcagacctt ccagctctgt ttggggctac 420
cttgagccag gagggcctcc aggggttcct tgtggaggct cacccagaca tgcctgcagc 480
cccattgccc caccaccccc agccccggtc aatgggtcag tctttattgc gctgcttcga 540
agattcgact gcaactttga cctcaaggtc ctaaatgccc agaaggctgg atatggtgcc 600
gctgtagtac acaatgtgaa ttccaatgaa cttctgaaca tggtgtggaa tagtgaggaa 660
atccagcagc agatctggat cccgtctgta tttattgggg agagaagctc cgagtacctg 720
cgtgccctct ttgtctacga gaagggggct cgggtgcttc tggttccaga caataccttc 780
cccttgggct attacctcat ccctttcaca gggattgtgg gactgctggt tttggccatg 840
ggagcagtaa tgatagctcg ttgtatccag caccggaaac ggctccagcg gaatcgactt 900
accaaagagc aactgaaaca gattcctaca catgactatc agaagggaga ccagtatgat 960
gtctgtgcca tttgcctgga tgaatatgag gatggggaca agctgcgggt actcccctgt 1020
gctcatgcct accacagccg ctgcgtggac ccctggctca ctcagacccg gaagacctgc 1080
cccatttgca agcagcctgt tcatcggggt cctggggacg aagaccaaga ggaagaaact 1140
caagggcaag aggagggtga tgaaggggag ccaagggacc accctgcctc agaaaggacc 1200
ccacttttgg gttctagccc cactcttccc acctcctttg gttccttagc cccagctccc 1260
cttgtttttc ctgggccttc aacagatccc ccactgtccc ctccctcttc ccctgttatc 1320
ctggtctaat aaccccccac acatacacct ctggtgacct atttgcacag accgtcgtct 1380
tccctccagt cttctgaggg ataggggaca ttccatccca agcttctccc ttacccacac 1440
ctatcctttt gaggggcttt ggggtggagc tggggcaagc agagggactg ggtcttcact 1500
tcttgggcta ataaaatttt tctttatgcc taaaaaaaaa aaaaaaaaaa a 1551
<210>11
<211>1551
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<220>
<221>CDS
<222>(640)..(1326)
<223>
<400>11
ggtcacctgt gttaggctcc gtcccctttc cgcgttttat ccccgtacca gaaaaggata 60
catttagtgc ctcccaccca gctccactaa acgggttgga tatctcattc tttgagttgg 120
tgttccttcc ccggcgcccc catgtagctg ggaagtggga cctgggggtg gttggacccc 180
tgggatccta aaggaggggc agggagggcg cagaactccg cttctgctcc ttgctaccag 240
gacgcgcggc ctcctcagcc tctttcctcc cgctgccatg caccctgcag ccttcccgct 300
tcctgtggtt gtggccgctg tgctgtgggg agcggccccg acccgggggc tcattcgagc 360
gacctcggac cacaatgcca gcatggactt tgcagacctt ccagctctgt ttggggctac 420
cttgagccag gagggcctcc aggggttcct tgtggaggct cacccagaca tgcctgcagc 480
cccattgccc caccaccccc agccccggtc aatgggtcag tctttattgc gctgcttcga 540
agattcgact gcaactttga cctcaaggtc ctaaatgccc agaaggctgg atatggtgcc 600
gctgtagtac acaatgtgaa ttccaatgaa cttctgaac atg gtg tgg aat agt 654
Met Val Trp Asn Ser
1 5
gag gaa atc cag cag cag atc tgg atc ccg tct gta ttt att ggg gag 702
Glu Glu Ile Gln Gln Gln Ile Trp Ile Pro Ser Val Phe Ile Gly Glu
10 15 20
aga agc tcc gag tac ctg cgt gcc ctc ttt gtc tac gag aag ggg gct 750
Arg Ser Ser Glu Tyr Leu Arg Ala Leu Phe Val Tyr Glu Lys Gly Ala
25 30 35
cgg gtg ctt ctg gtt cca gac aat acc ttc ccc ttg ggc tat tac ctc 798
Arg Val Leu Leu Val Pro Asp Asn Thr Phe Pro Leu Gly Tyr Tyr Leu
40 45 50
atc cct ttc aca ggg att gtg gga ctg ctg gtt ttg gcc atg gga gca 846
Ile Pro Phe Thr Gly Ile Val Gly Leu Leu Val Leu Ala Met Gly Ala
55 60 65
gta atg ata gct cgt tgt atc cag cac cgg aaa cgg ctc cag cgg aat 894
Val Met Ile Ala Arg Cys Ile Gln His Arg Lys Arg Leu Gln Arg Asn
70 75 80 85
cga ctt acc aaa gag caa ctg aaa cag att cct aca cat gac tat cag 942
Arg Leu Thr Lys Glu Gln Leu Lys Gln Ile Pro Thr His Asp Tyr Gln
90 95 100
aag gga gac cag tat gat gtc tgt gcc att tgc ctg gat gaa tat gag 990
Lys Gly Asp Gln Tyr Asp Val Cys Ala Ile Cys Leu Asp Glu Tyr Glu
105 110 115
gat ggg gac aag ctg cgg gta ctc ccc tgt gct cat gcc tac cac agc 1038
Asp Gly Asp Lys Leu Arg Val Leu Pro Cys Ala His Ala Tyr His Ser
120 125 130
cgc tgc gtg gac ccc tgg ctc act cag acc cgg aag acc tgc ccc att 1086
Arg Cys Val Asp Pro Trp Leu Thr Gln Thr Arg Lys Thr Cys Pro Ile
135 140 145
tgc aag cag cct gtt cat cgg ggt cct ggg gac gaa gac caa gag gaa 1134
Cys Lys Gln Pro Val His Arg Gly Pro Gly Asp Glu Asp Gln Glu Glu
150 155 160 165
gaa act caa ggg caa gag gag ggt gat gaa ggg gag cca agg gac cac 1182
Glu Thr Gln Gly Gln Glu Glu Gly Asp Glu Gly Glu Pro Arg Asp His
170 175 180
cct gcc tca gaa agg acc cca ctt ttg ggt tct agc ccc act ctt ccc 1230
Pro Ala Ser Glu Arg Thr Pro Leu Leu Gly Ser Ser Pro Thr Leu Pro
185 190 195
acc tcc ttt ggt tcc tta gcc cca gct ccc ctt gtt ttt cct ggg cct 1278
Thr Ser Phe Gly Ser Leu Ala Pro Ala Pro Leu Val Phe Pro Gly Pro
200 205 210
tca aca gat ccc cca ctg tcc cct ccc tct tcc cct gtt atc ctg gtc 1326
Ser Thr Asp Pro Pro Leu Ser Pro Pro Ser Ser Pro Val Ile Leu Val
215 220 225
taataacccc ccacacatac acctctggtg acctatttgc acagaccgtc gtcttccctc 1386
cagtcttctg agggataggg gacattccat cccaagcttc tcccttaccc acacctatcc 1446
ttttgagggg ctttggggtg gagctggggc aagcagaggg actgggtctt cacttcttgg 1506
gctaataaaa tttttcttta tgcctaaaaa aaaaaaaaaa aaaaa 1551
<210>12
<211>229
<212>PRT
＜213〉homo sapiens (Homo sapiens)
<400>12
Met Val Trp Asn Ser Glu Glu Ile Gln Gln Gln Ile Trp Ile Pro Ser
1 5 10 15
Val Phe Ile Gly Glu Arg Ser Ser Glu Tyr Leu Arg Ala Leu Phe Val
20 25 30
Tyr Glu Lys Gly Ala Arg Val Leu Leu Val Pro Asp Asn Thr Phe Pro
35 40 45
Leu Gly Tyr Tyr Leu Ile Pro Phe Thr Gly Ile Val Gly Leu Leu Val
50 55 60
Leu Ala Met Gly Ala Val Met Ile Ala Arg Cys Ile Gln His Arg Lys
65 70 75 80
Arg Leu Gln Arg Asn Arg Leu Thr Lys Glu Gln Leu Lys Gln Ile Pro
85 90 95
Thr His Asp Tyr Gln Lys Gly Asp Gln Tyr Asp Val Cys Ala Ile Cys
100 105 110
Leu Asp Glu Tyr Glu Asp Gly Asp Lys Leu Arg Val Leu Pro Cys Ala
115 120 125
His Ala Tyr His Ser Arg Cys Val Asp Pro Trp Leu Thr Gln Thr Arg
130 135 140
Lys Thr Cys Pro Ile Cys Lys Gln Pro Val His Arg Gly Pro Gly Asp
145 150 155 160
Glu Asp Gln Glu Glu Glu Thr Gln Gly Gln Glu Glu Gly Asp Glu Gly
165 170 175
Glu Pro Arg Asp His Pro Ala Ser Glu Arg Thr Pro Leu Leu Gly Ser
180 185 190
Ser Pro Thr Leu Pro Thr Ser Phe Gly Ser Leu Ala Pro Ala Pro Leu
195 200 205
Val Phe Pro Gly Pro Ser Thr Asp Pro Pro Leu Ser Pro Pro Ser Ser
210 215 220
Pro Val Ile Leu Val
225
<210>13
<211>1309
<212>DNA
＜213〉homo sapiens＜Homo sapiens)
<400>13
gacttcctgt tgcctgcagc cgcccacgca gaacatgaac ctgggccctg gagccctgac 60
tcagagcggc tccagccagg gcctgcactc tcagggcagc ctgagtgacg ccatcagcac 120
gggcctgcca ccctcctccc tcctgcaggg ccagattggc aacgggccga gccacgtgtc 180
catgcagcag acggcgccta acacgctgcc caccacctcc atgagcatct ctgggcccgg 240
ctacagccac gcgggacccg cctcgcaggg cgtccccatg caggggcaag gcaccatcgg 300
caactacgtg tctcggacca acatcaacat gcagtccaac ccagtctcca tgatgcagca 360
gcaggcggcc acgtcgcact acagctcggc gcagggcggc agccagcact accagggcca 420
gtcgtccatc gccatgatgg ggcagggcag ccaggggagc agcatgatgg ggcagcggcc 480
catggcgccc taccggccct cccagcaagg ctcttcccag cagtacctgg gccaggagga 540
gtactatggc gagcagtaca gccacagcca gggcgccgcg gagcccatgg gccagcagta 600
ctaccccgac ggccatggcg attacgccta ccagcagtca tcctacacgg agcagagcta 660
cgaccggtcc ttcgaggagt ccacgcagca ctactatgag gggggaaact cccagtacag 720
ccagcagcag gccgggtacc agcagggtgc cgcgcagcag cagacgtact cccagcagca 780
gtaccccagc cagcagagct accccgggca gcagcagggc tacgggtctg cccagggagc 840
cccgtcacag taccccggct accagcaagg ccaaggccag cagtacggaa gctaccgagc 900
accgcagaca gcgccgtctg cccagcagca gcggccctac ggctatgaac agggccagta 960
tggaaattac cagcagtaag ggacacacat tctggctgga gcccttgtgg tagcgtgttc 1020
atccaggggc cggatgggct ggcggcagct ctggtgaatt gtgacatgtt ggttacctgt 1080
tcgcccagtg ccacgtctgc atgtgaagcg tgctcatttc atgctgggac ctacttgctc 1140
agatctccaa gcaagcattt cttttctttt agggatgtct gaaagtcaca tccagttaca 1200
ttactgtgtt ctttctaatg aaaagtaaag gttttatata gaaaaaaaaa aaaaaaaaaa 1260
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaa 1309
<210>14
<211>1309
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<220>
<221>CDS
<222>(35)..(976)
<223>
<400>14
gacttcctgt tgcctgcagc cgcccacgca gaac atg aac ctg ggc cct gga gcc 55
Met Asn Leu Gly Pro Gly Ala
1 5
ctg act cag agc ggc tcc agc cag ggc ctg cac tct cag ggc agc ctg 103
Leu Thr Gln Ser Gly Ser Ser Gln Gly Leu His Ser Gln Gly Ser Leu
10 15 20
agt gac gcc atc agc acg ggc ctg cca ccc tcc tcc ctc ctg cag ggc 151
Ser Asp Ala Ile Ser Thr Gly Leu Pro Pro Ser Ser Leu Leu Gln Gly
25 30 35
cag att ggc aac ggg ccg agc cac gtg tcc atg cag cag acg gcg cct 199
Gln Ile Gly Asn Gly Pro Ser His Val Ser Met Gln Gln Thr Ala Pro
40 45 50 55
aac acg ctg ccc acc acc tcc atg agc atc tct ggg ccc ggc tac agc 247
Asn Thr Leu Pro Thr Thr Ser Met Ser Ile Ser Gly Pro Gly Tyr Ser
60 65 70
cac gcg gga ccc gcc tcg cag ggc gtc ccc atg cag ggg caa ggc acc 295
His Ala Gly Pro Ala Ser Gln Gly Val Pro Met Gln Gly Gln Gly Thr
75 80 85
atc ggc aac tac gtg tct cgg acc aac atc aac atg cag tcc aac cca 343
Ile Gly Asn Tyr Val Ser Arg Thr Asn Ile Asn Met Gln Ser Asn Pro
90 95 100
gtc tcc atg atg cag cag cag gcg gcc acg tcg cac tac agc tcg gcg 391
Val Ser Met Met Gln Gln Gln Ala Ala Thr Ser His Tyr Ser Ser Ala
105 110 115
cag ggc ggc agc cag cac tac cag ggc cag tcg tcc atc gcc atg atg 439
Gln Gly Gly Ser Gln His Tyr Gln Gly Gln Ser Ser Ile Ala Met Met
120 125 130 135
ggg cag ggc agc cag ggg agc agc atg atg ggg cag cgg ccc atg gcg 487
Gly Gln Gly Ser Gln Gly Ser Ser Met Met Gly Gln Arg Pro Met Ala
140 145 150
ccc tac cgg ccc tcc cag caa ggc tct tcc cag cag tac ctg ggc cag 535
Pro Tyr Arg Pro Ser Gln Gln Gly Ser Ser Gln Gln Tyr Leu Gly Gln
155 160 165
gag gag tac tat ggc gag cag tac agc cac agc cag ggc gcc gcg gag 583
Glu Glu Tyr Tyr Gly Glu Gln Tyr Ser His Ser Gln Gly Ala Ala Glu
170 175 180
ccc atg ggc cag cag tac tac ccc gac ggc cat ggc gat tac gcc tac 631
Pro Met Gly Gln Gln Tyr Tyr Pro Asp Gly His Gly Asp Tyr Ala Tyr
185 190 195
cag cag tca tcc tac acg gag cag agc tac gac cgg tcc ttc gag gag 679
Gln Gln Ser Ser Tyr Thr Glu Gln Ser Tyr Asp Arg Ser Phe Glu Glu
200 205 210 215
tcc acg cag cac tac tat gag ggg gga aac tcc cag tac agc cag cag 727
Ser Thr Gln His Tyr Tyr Glu Gly Gly Asn Ser Gln Tyr Ser Gln Gln
220 225 230
cag gcc ggg tac cag cag ggt gcc gcg cag cag cag acg tac tcc cag 775
Gln Ala Gly Tyr Gln Gln Gly Ala Ala Gln Gln Gln Thr Tyr Ser Gln
235 240 245
cag cag tac ccc agc cag cag agc tac ccc ggg cag cag cag ggc tac 823
Gln Gln Tyr Pro Ser Gln Gln Ser Tyr Pro Gly Gln Gln Gln Gly Tyr
250 255 260
ggg tct gcc cag gga gcc ccg tca cag tac ccc ggc tac cag caa ggc 871
Gly Ser Ala Gln Gly Ala Pro Ser Gln Tyr Pro Gly Tyr Gln Gln Gly
265 270 275
caa ggc cag cag tac gga agc tac cga gca ccg cag aca gcg ccg tct 919
Gln Gly Gln Gln Tyr Gly Ser Tyr Arg Ala Pro Gln Thr Ala Pro Ser
280 285 290 295
gcc cag cag cag cgg ccc tac ggc tat gaa cag ggc cag tat gga aat 967
Ala Gln Gln Gln Arg Pro Tyr Gly Tyr Glu Gln Gly Gln Tyr Gly Asn
300 305 310
tac cag cag taagggacac acattctggc tggagccctt gtggtagcgt 1016
Tyr Gln Gln
gttcatccag gggccggatg ggctggcggc agctctggtg aattgtgaca tgttggttac 1076
ctgttcgccc agtgccacgt ctgcatgtga agcgtgctca tttcatgctg ggacctactt 1136
gctcagatct ccaagcaagc atttcttttc ttttagggat gtctgaaagt cacatccagt 1196
tacattactg tgttctttct aatgaaaagt aaaggtttta tatagaaaaa aaaaaaaaaa 1256
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 1309
<210>15
<211>314
<212>PRT
＜213〉homo sapiens (Homo sapiens)
<400>15
Met Asn Leu Gly Pro Gly Ala Leu Thr Gln Ser Gly Ser Ser Gln Gly
1 5 10 15
Leu His Ser Gln Gly Ser Leu Ser Asp Ala Ile Ser Thr Gly Leu Pro
20 25 30
Pro Ser Ser Leu Leu Gln Gly Gln Ile Gly Asn Gly Pro Ser His Val
35 40 45
Ser Met Gln Gln Thr Ala Pro Asn Thr Leu Pro Thr Thr Ser Met Ser
50 55 60
Ile Ser Gly Pro Gly Tyr Ser His Ala Gly Pro Ala Ser Gln Gly Val
65 70 75 80
Pro Met Gln Gly Gln Gly Thr Ile Gly Asn Tyr Val Ser Arg Thr Asn
85 90 95
Ile Asn Met Gln Ser Asn Pro Val Ser Met Met Gln Gln Gln Ala Ala
100 105 110
Thr Ser His Tyr Ser Ser Ala Gln Gly Gly Ser Gln His Tyr Gln Gly
115 120 125
Gln Ser Ser Ile Ala Met Met Gly Gln Gly Ser Gln Gly Ser Ser Met
130 135 140
Met Gly Gln Arg Pro Met Ala Pro Tyr Arg Pro Ser Gln Gln Gly Ser
145 150 155 160
Ser Gln Gln Tyr Leu Gly Gln Glu Glu Tyr Tyr Gly Glu Gln Tyr Ser
165 170 175
His Ser Gln Gly Ala Ala Glu Pro Met Gly Gln Gln Tyr Tyr Pro Asp
180 185 190
Gly His Gly Asp Tyr Ala Tyr Gln Gln Ser Ser Tyr Thr Glu Gln Ser
195 200 205
Tyr Asp Arg Ser Phe Glu Glu Ser Thr Gln His Tyr Tyr Glu Gly Gly
210 215 220
Asn Ser Gln Tyr Ser Gln Gln Gln Ala Gly Tyr Gln Gln Gly Ala Ala
225 230 235 240
Gln Gln Gln Thr Tyr Ser Gln Gln Gln Tyr Pro Ser Gln Gln Ser Tyr
245 250 255
Pro Gly Gln Gln Gln Gly Tyr Gly Ser Ala Gln Gly Ala Pro Ser Gln
260 265 270
Tyr Pro Gly Tyr Gln Gln Gly Gln Gly Gln Gln Tyr Gly Ser Tyr Arg
275 280 285
Ala Pro Gln Thr Ala Pro Ser Ala Gln Gln Gln Arg Pro Tyr Gly Tyr
290 295 300
Glu Gln Gly Gln Tyr Gly Asn Tyr Gln Gln
305 310
<210>16
<211>1708
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<400>16
gtgcaaacag catgttctga atgtgcctgt actctgttcg tgcttctctt tgcagctgtg 60
caagttcatt cgcaaacgtc ctagaagtgg aactgctggg tcaaagtgca ttccccaaat 120
gtcctgccag aggcctggtc ggcagcagcc tcctgcacag cccgagtccc ttctgcgaga 180
gtcctggctt gtttgcagcc tgcagctggg agatttgaag tcagacttcc aggattgccg 240
catggagctg cagagggagt gagcatgggg ctggaggacc tgccccgccg gctgacactc 300
ccacagcaag gcggccccgc caaggaagca ctccacatcc gctagtaggg tttgtctgca 360
tcttttcagt tcttcagttt aagtcctgcc tgggaagaaa gcaaactcca gaggcaaatc 420
tggaatgcct gtgtgccacc ttctcaccgc accacagact cccctgagga cgggttgtgg 480
cggggttggc cccaagcatg ggaggcagcg cagacatgca gaatggggtc tgaggtcacg 540
ttgcaacgct ggcaggatgt gtgctcaagg gccagtctct gcaggggtca gggcgtgtgg 600
gccacgcaca aggagctggc actaagccgc ttaggctgca ggaagacacc atctgcctgg 660
ggcggacaag gccccatgtc cgtcctcaag gaggctggtc tggatgagaa gggtcacagt 720
ctggccagga gtgtcaccgt gccccctgac cccatctggg gtcgggctgg acaggtcctc 780
aggcctagac gtgggcccag ccagaacctt ctcccctggc atgtctcttc caggcctagt 840
tccagagctg tcattcttcg gcgagccgcg ctgcacgcca gcctccagtc tggcagttaa 900
acctcactat gaaaatctgc ttttgggatt ttatttgcat ttccattaga ctgagcgcat 960
cacaagccac ttcaggatag actgaggtgc agagggaggg gacaagcggc caggttgact 1020
agaagagcac agaacctggc tgtctcgaag agggcagctt gttccaggga accaatgaac 1080
tgtcagtaaa ggggattgtg gcttcctagt gaggcaagaa atgatgctcc cttcatcctg 1140
ccagggctca ggacaagagc tacttaatgg tttgattatt attatttttt aagagatgtt 1200
gtccaggctg gagtgcagtg atgcaatcat ggcttactgc agcctcaaac tcctggcctc 1260
aggccatcct cctgcctcag cctcccaaag tgctgtgatc acaggcacga gccactgcat 1320
cctgccttta aatggttttt tggggcccct tttggatgct ctgggtgttt ttgccaagag 1380
ttacaggatg tcaagtgtgg ggagctcagc acccttgctg tggaccagtg aaggctgttc 1440
cagaccaggt gcttccagac atttccaggc tccaggagag aggctgggag cccccacaga 1500
aagcacagga aaatgcaaaa aaaaaaaaac agtctttttt tttttttttt gctttttatt 1560
atgaaaacaa aacaaatgcc ccaggagaag ggtccatgat taccagaaac atcaaagagt 1620
actttctacc atttttattc tgttgtgttg aggccagcat tgcaataaac aagctaaact 1680
acttaaaaaa aaaaaaaaaa aaaaaaaa 1708
<210>17
<211>1708
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<220>
<221>CDS
<222>(523)..(897)
<223>
<400>17
gtgcaaacag catgttctga atgtgcctgt actctgttcg tgcttctctt tgcagctgtg 60
caagttcatt cgcaaacgtc ctagaagtgg aactgctggg tcaaagtgca ttccccaaat 120
gtcctgccag aggcctggtc ggcagcagcc tcctgcacag cccgagtccc ttctgcgaga 180
gtcctggctt gtttgcagcc tgcagctggg agatttgaag tcagacttcc aggattgccg 240
catggagctg cagagggagt gagcatgggg ctggaggacc tgccccgccg gctgacactc 300
ccacagcaag gcggccccgc caaggaagca ctccacatcc gctagtaggg tttgtctgca 360
tcttttcagt tcttcagttt aagtcctgcc tgggaagaaa gcaaactcca gaggcaaatc 420
tggaatgcct gtgtgccacc ttctcaccgc accacagact cccctgagga cgggttgtgg 480
cggggttggc cccaagcatg ggaggcagcg cagacatgca ga atg ggg tct gag 534
Met Gly Ser Glu
1
gtc acg ttg caa cgc tgg cag gat gtg tgc tca agg gcc agt ctc tgc 582
Val Thr Leu Gln Arg Trp Gln Asp Val Cys Ser Arg Ala Ser Leu Cys
5 10 15 20
agg ggt cag ggc gtg tgg gcc acg cac aag gag ctg gca cta agc cgc 630
Arg Gly Gln Gly Val Trp Ala Thr His Lys Glu Leu Ala Leu Ser Arg
25 30 35
tta ggc tgc agg aag aca cca tct gcc tgg ggc gga caa ggc ccc atg 678
Leu Gly Cys Arg Lys Thr Pro Ser Ala Trp Gly Gly Gln Gly Pro Met
40 45 50
tcc gtc ctc aag gag gct ggt ctg gat gag aag ggt cac agt ctg gcc 726
Ser Val Leu Lys Glu Ala Gly Leu Asp Glu Lys Gly His Ser Leu Ala
55 60 65
agg agt gtc acc gtg ccc cct gac ccc atc tgg ggt cgg gct gga cag 774
Arg Ser Val Thr Val Pro Pro Asp Pro Ile Trp Gly Arg Ala Gly Gln
70 75 80
gtc ctc agg cct aga cgt ggg ccc agc cag aac ctt ctc ccc tgg cat 822
Val Leu Arg Pro Arg Arg Gly Pro Ser Gln Asn Leu Leu Pro Trp His
85 90 95 100
gtc tct tcc agg cct agt tcc aga gct gtc att ctt cgg cga gcc gcg 870
Val Ser Ser Arg Pro Ser Ser Arg Ala Val Ile Leu Arg Arg Ala Ala
105 110 115
ctg cac gcc agc ctc cag tct ggc agt taaacctcac tatgaaaatc 917
Leu His Ala Ser Leu Gln Ser Gly Ser
120 125
tgcttttggg attttatttg catttccatt agactgagcg catcacaagc cacttcagga 977
tagactgagg tgcagaggga ggggacaagc ggccaggttg actagaagag cacagaacct 1037
ggctgtctcg aagagggcag cttgttccag ggaaccaatg aactgtcagt aaaggggatt 1097
gtggcttcct agtgaggcaa gaaatgatgc tcccttcatc ctgccagggc tcaggacaag 1157
agctacttaa tggtttgatt attattattt tttaagagat gttgtccagg ctggagtgca 1217
gtgatgcaat catggcttac tgcagcctca aactcctggc ctcaggccat cctcctgcct 1277
cagcctccca aagtgctgtg atcacaggca cgagccactg catcctgcct ttaaatggtt 1337
ttttggggcc ccttttggat gctctgggtg tttttgccaa gagttacagg atgtcaagtg 1397
tggggagctc agcacccttg ctgtggacca gtgaaggctg ttccagacca ggtgcttcca 1457
gacatttcca ggctccagga gagaggctgg gagcccccac agaaagcaca ggaaaatgca 1517
aaaaaaaaaa aacagtcttt tttttttttt tttgcttttt attatgaaaa caaaacaaat 1577
gccccaggag aagggtccat gattaccaga aacatcaaag agtactttct accattttta 1637
ttctgttgtg ttgaggccag cattgcaata aacaagctaa actacttaaa aaaaaaaaaa 1697
aaaaaaaaaa a 1708
<210>18
<211>125
<212>PRT
＜213〉homo sapiens (Homo sapiens)
<400>18
Met Gly Ser Glu Val Thr Leu Gln Arg Trp Gln Asp Val Cys Ser Arg
1 5 10 15
Ala Ser Leu Cys Arg Gly Gln Gly Val Trp Ala Thr His Lys Glu Leu
20 25 30
Ala Leu Ser Arg Leu Gly Cys Arg Lys Thr Pro Ser Ala Trp Gly Gly
35 40 45
Gln Gly Pro Met Ser Val Leu Lys Glu Ala Gly Leu Asp Glu Lys Gly
50 55 60
His Ser Leu Ala Arg Ser Val Thr Val Pro Pro Asp Pro Ile Trp Gly
65 70 75 80
Arg Ala Gly Gln Val Leu Arg Pro Arg Arg Gly Pro Ser Gln Asn Leu
85 90 95
Leu Pro Trp His Val Ser Ser Arg Pro Ser Ser Arg Ala Val Ile Leu
100 105 110
Arg Arg Ala Ala Leu His Ala Ser Leu Gln Ser Gly Ser
115 120 125
<210>19
<211>1191
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<400>19
ggcggcgggg ctggcgcggc tcctgttgct cctcgggctc tcggccggcg ggcccgcgcc 60
ggcaggtgca gcgaagatga aggtggtgga ggagcccaac gcgtttgggg tgaacaaccc 120
gttcttgcct caggccagtc gcctccaggc caagagggat ccttcacccg tgtctggacc 180
cgtgcatctc ttccgactct cgggcaagtg cttcagcctg gtggagtcca cgtacaagta 240
tgagttctgc ccgttccaca acgtgaccca gcacgagcag accttccgct ggaacgccta 300
cagtgggatc ctcggcatct ggcacgagtg ggagatcgcc aacaacacct tcacgggcat 360
gtggatgagg gacggtgacg cctgccgttc ccggagccgg cagagcaagg tggagctggc 420
gtgtggaaaa agcaaccggc tggcccatgt gtccgagccg agcacctgcg tctacgcgct 480
gacgttcgag acccccctcg tctgccaccc ccacgccttg ctagtgtacc caaccctgcc 540
agaggccctg cagcggcagt gggaccaggt agagcaggac ctggccgatg agctgatcac 600
cccccagggc catgagaagt tgctgaggac actttttgag gatgctggct acttaaagac 660
cccagaagaa aatgaaccca cccagctgga gggaggtcct gacagcttgg ggtttgagac 720
cctggaaaac tgcaggaagg ctcataaaga actctcaaag gagatcaaaa ggctgaaagg 780
tttgctcacc cagcacggca tcccctacac gaggcccaca gaaacttcca acttggagca 840
cttgggccac gagacgccca gagccaagtc tccagagcag ctgcggggtg acccaggact 900
gcgtgggagt ttgtgacctt gtggtgggag agcagaggtg gacgcggccg agagccctac 960
agagaagctg gctggtagga cccgcaggga ccagctgacc aggcttgtgc tcagagaagc 1020
agacaaacaa agattcaagg ttttaattaa ttcccatact gataaaaata actccatgaa 1080
ttctgtaaac cattgcataa atgctatagt gtaaaaaaat ttaaacaagt gttaacttta 1140
aacagttcgc tacaagtaaa tgattataaa tactaaaaaa aaaaaaaaaa a 1191
<210>20
<211>1191
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<220>
<221>CDS
<222>(77)..(913)
<223>
<400>20
ggcggcgggg ctggcgcggc tcctgttgct cctcgggctc tcggccggcg ggcccgcgcc 60
ggcaggtgca gcgaag atg aag gtg gtg gag gag ccc aac gcg ttt ggg gtg 112
Met Lys Val Val Glu Glu Pro Asn Ala Phe Gly Val
1 5 10
aac aac ccg ttc ttg cct cag gcc agt cgc ctc cag gcc aag agg gat 160
Asn Asn Pro Phe Leu Pro Gln Ala Ser Arg Leu Gln Ala Lys Arg Asp
15 20 25
cct tca ccc gtg tct gga ccc gtg cat ctc ttc cga ctc tcg ggc aag 208
Pro Ser Pro Val Ser Gly Pro Val His Leu Phe Arg Leu Ser Gly Lys
30 35 40
tgc ttc agc ctg gtg gag tcc acg tac aag tat gag ttc tgc ccg ttc 256
Cys Phe Ser Leu Val Glu Ser Thr Tyr Lys Tyr Glu Phe Cys Pro Phe
45 50 55 60
cac aac gtg acc cag cac gag cag acc ttc cgc tgg aac gcc tac agt 304
His Asn Val Thr Gln His Glu Gln Thr Phe Arg Trp Asn Ala Tyr Ser
65 70 75
ggg atc ctc ggc atc tgg cac gag tgg gag atc gcc aac aac acc ttc 352
Gly Ile Leu Gly Ile Trp His Glu Trp Glu Ile Ala Asn Asn Thr Phe
80 85 90
acg ggc atg tgg atg agg gac ggt gac gcc tgc cgt tcc cgg agc cgg 400
Thr Gly Met Trp Met Arg Asp Gly Asp Ala Cys Arg Ser Arg Ser Arg
95 100 105
cag agc aag gtg gag ctg gcg tgt gga aaa agc aac cgg ctg gcc cat 448
Gln Ser Lys Val Glu Leu Ala Cys Gly Lys Ser Asn Arg Leu Ala His
110 115 120
gtg tcc gag ccg agc acc tgc gtc tac gcg ctg acg ttc gag acc ccc 496
Val Ser Glu Pro Ser Thr Cys Val Tyr Ala Leu Thr Phe Glu Thr Pro
125 130 135 140
ctc gtc tgc cac ccc cac gcc ttg cta gtg tac cca acc ctg cca gag 544
Leu Val Cys His Pro His Ala Leu Leu Val Tyr Pro Thr Leu Pro Glu
145 150 155
gcc ctg cag cgg cag tgg gac cag gta gag cag gac ctg gcc gat gag 592
Ala Leu Gln Arg Gln Trp Asp Gln Val Glu Gln Asp Leu Ala Asp Glu
160 165 170
ctg atc acc ccc cag ggc cat gag aag ttg ctg agg aca ctt ttt gag 640
Leu Ile Thr Pro Gln Gly His Glu Lys Leu Leu Arg Thr Leu Phe Glu
175 180 185
gat gct ggc tac tta aag acc cca gaa gaa aat gaa ccc acc cag ctg 688
Asp Ala Gly Tyr Leu Lys Thr Pro Glu Glu Asn Glu Pro Thr Gln Leu
190 195 200
gag gga ggt cct gac agc ttg ggg ttt gag acc ctg gaa aac tgc agg 736
Glu Gly Gly Pro Asp Ser Leu Gly Phe Glu Thr Leu Glu Asn Cys Arg
205 210 215 220
aag gct cat aaa gaa ctc tca aag gag atc aaa agg ctg aaa ggt ttg 784
Lys Ala His Lys Glu Leu Ser Lys Glu Ile Lys Arg Leu Lys Gly Leu
225 230 235
ctc acc cag cac ggc atc ccc tac acg agg ccc aca gaa act tcc aac 832
Leu Thr Gln His Gly Ile Pro Tyr Thr Arg Pro Thr Glu Thr Ser Asn
240 245 250
ttg gag cac ttg ggc cac gag acg ccc aga gcc aag tct cca gag cag 880
Leu Glu His Leu Gly His Glu Thr Pro Arg Ala Lys Ser Pro Glu Gln
255 260 265
ctg cgg ggt gac cca gga ctg cgt ggg agt ttg tgaccttgtg gtgggagagc 933
Leu Arg Gly Asp Pro Gly Leu Arg Gly Ser Leu
270 275
agaggtggac gcggccgaga gccctacaga gaagctggct ggtaggaccc gcagggacca 993
gctgaccagg cttgtgctca gagaagcaga caaacaaaga ttcaaggttt taattaattc 1053
ccatactgat aaaaataact ccatgaattc tgtaaaccat tgcataaatg ctatagtgta 1113
aaaaaattta aacaagtgtt aactttaaac agttcgctac aagtaaatga ttataaatac 1173
taaaaaaaaa aaaaaaaa 1191
<210>21
<211>279
<212>PRT
＜213〉homo sapiens (Homo sapiens)
<400>21
Met Lys Val Val Glu Glu Pro Asn Ala Phe Gly Val Asn Asn Pro Phe
1 5 10 15
Leu Pro Gln Ala Ser Arg Leu Gln Ala Lys Arg Asp Pro Ser Pro Val
20 25 30
Ser Gly Pro Val His Leu Phe Arg Leu Ser Gly Lys Cys Phe Ser Leu
35 40 45
Val Glu Ser Thr Tyr Lys Tyr Glu Phe Cys Pro Phe His Asn Val Thr
50 55 60
Gln His Glu Gln Thr Phe Arg Trp Asn Ala Tyr Ser Gly Ile Leu Gly
65 70 75 80
Ile Trp His Glu Trp Glu Ile Ala Asn Asn Thr Phe Thr Gly Met Trp
85 90 95
Met Arg Asp Gly Asp Ala Cys Arg Ser Arg Ser Arg Gln Ser Lys Val
100 105 110
Glu Leu Ala Cys Gly Lys Ser Asn Arg Leu Ala His Val Ser Glu Pro
115 120 125
Ser Thr Cys Val Tyr Ala Leu Thr Phe Glu Thr Pro Leu Val Cys His
130 135 140
Pro His Ala Leu Leu Val Tyr Pro Thr Leu Pro Glu Ala Leu Gln Arg
145 150 155 160
Gln Trp Asp Gln Val Glu Gln Asp Leu Ala Asp Glu Leu Ile Thr Pro
165 170 175
Gln Gly His Glu Lys Leu Leu Arg Thr Leu Phe Glu Asp Ala Gly Tyr
180 185 190
Leu Lys Thr Pro Glu Glu Asn Glu Pro Thr Gln Leu Glu Gly Gly Pro
195 200 205
Asp Ser Leu Gly Phe Glu Thr Leu Glu Asn Cys Arg Lys Ala His Lys
210 215 220
Glu Leu Ser Lys Glu Ile Lys Arg Leu Lys Gly Leu Leu Thr Gln His
225 230 235 240
Gly Ile Pro Tyr Thr Arg Pro Thr Glu Thr Ser Asn Leu Glu His Leu
245 250 255
Gly His Glu Thr Pro Arg Ala Lys Ser Pro Glu Gln Leu Arg Gly Asp
260 265 270
Pro Gly Leu Arg Gly Ser Leu
275
<210>22
<211>1493
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<400>22
gggctaacat cagccaggag ggtgtcactg gtgagggatg cgttgacagc caggggtccc 60
catgagcccc tggagcaggc ccctcccagc ctgggcctcg caaagggcag ctgcagacca 120
gaggttggga ggcagccggt ggtggggcag gaggagctgg gaggtggcgc ctgggacagg 180
cagggctgcg gcgtgtgtgg gtgccagtct gcgtggtctc cttgtgcaca cacacccctc 240
cccagctcgg tgtctatacc atccctgctg gcgtcgtctg cctgctgtcc accatctgcc 300
tgtgggagag tgtgcccccc accccgccct ctgccggggc tgccagctcc acctcagaga 360
agttcctgga tgggctcaag ctgcagctca tgtggaacaa ggcctatgtc atcctggctg 420
tgtgcttggg gggaatgatc gggatctctg ccagcttctc agccctcctg gagcagatcc 480
tctgtgcaag cggccactcc agtgggtttt ccggcctctg tggcgctctc ttcatcacgt 540
ttgggatcct gggggcactg gctctcggcc cctatgtgga ccggaccaag cacttcactg 600
aggccaccaa gattggcctg tgcctgttct ctctggcctg cgtgcccttt gccctggtgt 660
cccagctgca gggacagacc cttgccctgg ctgccacctg ctcgctgctc gggctgtttg 720
gcttctcggt gggccccgtg gccatggagt tggcggtcga gtgttccttc cccgtggggg 780
agggggctgc cacaggcatg atctttgtgc tggggcaggc cgagggaata ctcatcatgc 840
tggcaatgac ggcactgact gtgcgacgct cggagccgtc cttgtccacc tgccagcagg 900
gggaggatcc acttgactgg acagtgtctc tgctgctgat ggccggcctg tgcaccttct 960
tcagctgcat cctggcggtc ttcttccaca ccccataccg gcgcctgcag gccgagtctg 1020
gggagccccc ctccacccgt aacgccgtgg gcggcgcaga ctcagggccg ggtgtggacc 1080
gagggggagc aggaagggct ggggtcctgg ggcccagcac ggcgactccg gagtgcacgg 1140
cgaggggggc ctcgctagag gaccccagag ggcccgggag cccccaccca gcctgccacc 1200
gagcgactcc ccgtgcgcaa ggcccagcag ccaccgacgc gccctcccgc cccggcagac 1260
tcgcaggcag ggtccaagcg tccaggttta ttgacccggc tgggtctcac tcctccttct 1320
cctccccgtg ggtgatcacg tagctgagcg ccttgtagtc caggttgccc gccacatcga 1380
tggaggcgaa ctggaacatc tggtccacct gcgggcgggg gcgaaagggc tccttgcggg 1440
ctccgggagc gaattacaag cgcgtacctg caaaaaaaaa aaaaaaaaaa aat 1493
<210>23
<211>1493
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<220>
<221>CDS
<222>(390)..(1340)
<223>
<400>23
gggctaacat cagccaggag ggtgtcactg gtgagggatg cgttgacagc caggggtccc 60
catgagcccc tggagcaggc ccctcccagc ctgggcctcg caaagggcag ctgcagacca 120
gaggttggga ggcagccggt ggtggggcag gaggagctgg gaggtggcgc ctgggacagg 180
cagggctgcg gcgtgtgtgg gtgccagtct gcgtggtctc cttgtgcaca cacacccctc 240
cccagctcgg tgtctatacc atccctgctg gcgtcgtctg cctgctgtcc accatctgcc 300
tgtgggagag tgtgcccccc accccgccct ctgccggggc tgccagctcc acctcagaga 360
agttcctgga tgggctcaag ctgcagctc atg tgg aac aag gcc tat gtc atc 413
Met Trp Asn Lys Ala Tyr Val Ile
1 5
ctg gct gtg tgc ttg ggg gga atg atc ggg atc tct gcc agc ttc tca 461
Leu Ala Val Cys Leu Gly Gly Met Ile Gly Ile Ser Ala Ser Phe Ser
10 15 20
gcc ctc ctg gag cag atc ctc tgt gca agc ggc cac tcc agt ggg ttt 509
Ala Leu Leu Glu Gln Ile Leu Cys Ala Ser Gly His Ser Ser Gly Phe
25 30 35 40
tcc ggc ctc tgt ggc gct ctc ttc atc acg ttt ggg atc ctg ggg gca 557
Ser Gly Leu Cys Gly Ala Leu Phe Ile Thr Phe Gly Ile Leu Gly Ala
45 50 55
ctg gct ctc ggc ccc tat gtg gac cgg acc aag cac ttc act gag gcc 605
Leu Ala Leu Gly Pro Tyr Val Asp Arg Thr Lys His Phe Thr Glu Ala
60 65 70
acc aag att ggc ctg tgc ctg ttc tct ctg gcc tgc gtg ccc ttt gcc 653
Thr Lys Ile Gly Leu Cys Leu Phe Ser Leu Ala Cys Val Pro Phe Ala
75 80 85
ctg gtg tcc cag ctg cag gga cag acc ctt gcc ctg gct gcc acc tgc 701
Leu Val Ser Gln Leu Gln Gly Gln Thr Leu Ala Leu Ala Ala Thr Cys
90 95 100
tcg ctg ctc ggg ctg ttt ggc ttc tcg gtg ggc ccc gtg gcc atg gag 749
Ser Leu Leu Gly Leu Phe Gly Phe Ser Val Gly Pro Val Ala Met Glu
105 110 115 120
ttg gcg gtc gag tgt tcc ttc ccc gtg ggg gag ggg gct gcc aca ggc 797
Leu Ala Val Glu Cys Ser Phe Pro Val Gly Glu Gly Ala Ala Thr Gly
125 130 135
atg atc ttt gtg ctg ggg cag gcc gag gga ata ctc atc atg ctg gca 845
Met Ile Phe Val Leu Gly Gln Ala Glu Gly Ile Leu Ile Met Leu Ala
140 145 150
atg acg gca ctg act gtg cga cgc tcg gag ccg tcc ttg tcc acc tgc 893
Met Thr Ala Leu Thr Val Arg Arg Ser Glu Pro Ser Leu Ser Thr Cys
155 160 165
cag cag ggg gag gat cca ctt gac tgg aca gtg tct ctg ctg ctg atg 941
Gln Gln Gly Glu Asp Pro Leu Asp Trp Thr Val Ser Leu Leu Leu Met
170 175 180
gcc ggc ctg tgc acc ttc ttc agc tgc atc ctg gcg gtc ttc ttc cac 989
Ala Gly Leu Cys Thr Phe Phe Ser Cys Ile Leu Ala Val Phe Phe His
185 190 195 200
acc cca tac cgg cgc ctg cag gcc gag tct ggg gag ccc ccc tcc acc 1037
Thr Pro Tyr Arg Arg Leu Gln Ala Glu Ser Gly Glu Pro Pro Ser Thr
205 210 215
cgt aac gcc gtg ggc ggc gca gac tca ggg ccg ggt gtg gac cga ggg 1085
Arg Asn Ala Val Gly Gly Ala Asp Ser Gly Pro Gly Val Asp Arg Gly
220 225 230
gga gca gga agg gct ggg gtc ctg ggg ccc agc acg gcg act ccg gag 1133
Gly Ala Gly Arg Ala Gly Val Leu Gly Pro Ser Thr Ala Thr Pro Glu
235 240 245
tgc acg gcg agg ggg gcc tcg cta gag gac ccc aga ggg ccc ggg agc 1181
Cys Thr Ala Arg Gly Ala Ser Leu Glu Asp Pro Arg Gly Pro Gly Ser
250 255 260
ccc cac cca gcc tgc cac cga gcg act ccc cgt gcg caa ggc cca gca 1229
Pro His Pro Ala Cys His Arg Ala Thr Pro Arg Ala Gln Gly Pro Ala
265 270 275 280
gcc acc gac gcg ccc tcc cgc ccc ggc aga ctc gca ggc agg gtc caa 1277
Ala Thr Asp Ala Pro Ser Arg Pro Gly Arg Leu Ala Gly Arg Val Gln
285 290 295
gcg tcc agg ttt att gac ccg gct ggg tct cac tcc tcc ttc tcc tcc 1325
Ala Ser Arg Phe Ile Asp Pro Ala Gly Ser His Ser Ser Phe Ser Ser
300 305 310
ccg tgg gtg atc acg tagctgagcg ccttgtagtc caggttgccc gccacatcga 1380
Pro Trp Val Ile Thr
315
tggaggcgaa ctggaacatc tggtccacct gcgggcgggg gcgaaagggc tccttgcggg 1440
ctccgggagc gaattacaag cgcgtacctg caaaaaaaaa aaaaaaaaaa aat 1493
<210>24
<211>317
<212>PRT
＜213〉homo sapiens (Homo sapiens)
<400>24
Met Trp Asn Lys Ala Tyr Val Ile Leu Ala Val Cys Leu Gly Gly Met
1 5 10 15
Ile Gly Ile Ser Ala Ser Phe Ser Ala Leu Leu Glu Gln Ile Leu Cys
20 25 30
Ala Ser Gly His Ser Ser Gly Phe Ser Gly Leu Cys Gly Ala Leu Phe
35 40 45
Ile Thr Phe Gly Ile Leu Gly Ala Leu Ala Leu Gly Pro Tyr Val Asp
50 55 60
Arg Thr Lys His Phe Thr Glu Ala Thr Lys Ile Gly Leu Cys Leu Phe
65 70 75 80
Ser Leu Ala Cys Val Pro Phe Ala Leu Val Ser Gln Leu Gln Gly Gln
85 90 95
Thr Leu Ala Leu Ala Ala Thr Cys Ser Leu Leu Gly Leu Phe Gly Phe
100 105 110
Ser Val Gly Pro Val Ala Met Glu Leu Ala Val Glu Cys Ser Phe Pro
115 120 125
Val Gly Glu Gly Ala Ala Thr Gly Met Ile Phe Val Leu Gly Gln Ala
130 135 140
Glu Gly Ile Leu Ile Met Leu Ala Met Thr Ala Leu Thr Val Arg Arg
145 150 155 160
Ser Glu Pro Ser Leu Ser Thr Cys Gln Gln Gly Glu Asp Pro Leu Asp
165 170 175
Trp Thr Val Ser Leu Leu Leu Met Ala Gly Leu Cys Thr Phe Phe Ser
180 185 190
Cys Ile Leu Ala Val Phe Phe His Thr Pro Tyr Arg Arg Leu Gln Ala
195 200 205
Glu Ser Gly Glu Pro Pro Ser Thr Arg Asn Ala Val Gly Gly Ala Asp
210 215 220
Ser Gly Pro Gly Val Asp Arg Gly Gly Ala Gly Arg Ala Gly Val Leu
225 230 235 240
Gly Pro Ser Thr Ala Thr Pro Glu Cys Thr Ala Arg Gly Ala Ser Leu
245 250 255
Glu Asp Pro Arg Gly Pro Gly Ser Pro His Pro Ala Cys His Arg Ala
260 265 270
Thr Pro Arg Ala Gln Gly Pro Ala Ala Thr Asp Ala Pro Ser Arg Pro
275 280 285
Gly Arg Leu Ala Gly Arg Val Gln Ala Ser Arg Phe Ile Asp Pro Ala
290 295 300
Gly Ser His Ser Ser Phe Ser Ser Pro Trp Val Ile Thr
305 310 315
<210>25
<211>1284
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<400>25
gggcagaggc atatggcaag aaagagtgga agcacttctt gtcggacact ggaatggctt 60
gccgctcagg aaagtattac ttttacgaca actactttga cctgccagga gctcttctgt 120
gtgccagggt ggtggactat ttaacaaaac tgaacaatgg tcaaaaaaca tttgattttt 180
ggaaggatat agttgctgct atacaacaca attataaaat gtcagctttt aaggaaaact 240
gtggaatata ttttccagaa ataaaaagag atccaggcag atatttacat agttgtcctg 300
aatctgtgaa aaaatggctt cgacagctaa agaatgctgg gaaaattctt ctgttaatta 360
ccagttctca cagtgattac tgtagacttc tctgcgaata tattcttggg aatgatttta 420
cagacctttt tgacattgtg attacaaatg cattgaagcc tggtttcttc tcccacttac 480
caagtcagag acctttccgg acactcgaga atgatgagga gcaggaggca ctgccatctc 540
tggataaacc tggctggtac tcccaaggga acgctgtcca cctctatgaa cttctgaaga 600
aaatgactgg caaacctgaa cccaaggttg tttattttgg tgacagcatg cattcagata 660
ttttcccagc tcgtcactat agtaattggg agacagtcct catcctggaa gaactcagag 720
ggggatgaag gcacgaggag tcagaggcct gaggagtcag agcctctaga gaagaaagga 780
aaatatgagg gaccaaaagc aaaaccttta aatacttcat ctaaaaaatg gggctctttt 840
tttattgatt cagttttggg actggaaaat acagaagact ccttggttta tacatggtct 900
tgtaagagaa tcagtactta cagcactatt gcaattccaa gtattgaagc aatcgcagaa 960
ttacctctgg actacaaatt tacaagattc tcttcaagca attcaaaaac agctggctac 1020
tatccaaatc ctccactggt cttatcaagt gatgagacac tgatatccaa ataagttgtc 1080
tttactgaaa aatgaagtga agacccatat atgcagttaa aaaaaagtta attttcaaaa 1140
aatactgtaa aagactttaa ggaacaagtt ttattgacca ataagttgat atttgtccat 1200
aggtctcctt tctataaatc atcttgatgt ttaacaactc ttattatatt aaaatctcag 1260
tatcctaaaa aaaaaaaaaa aaaa 1284
<210>26
<211>1284
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<220>
<221>CDS
<222>(54)..(725)
<223>
<400>26
gggcagaggc atatggcaag aaagagtgga agcacttctt gtcggacact gga atg 56
Met
1
gct tgc cgc tca gga aag tat tac ttt tac gac aac tac ttt gac ctg 104
Ala Cys Arg Ser Gly Lys Tyr Tyr Phe Tyr Asp Asn Tyr Phe Asp Leu
5 10 15
cca gga gct ctt ctg tgt gcc agg gtg gtg gac tat tta aca aaa ctg 152
Pro Gly Ala Leu Leu Cys Ala Arg Val Val Asp Tyr Leu Thr Lys Leu
20 25 30
aac aat ggt caa aaa aca ttt gat ttt tgg aag gat ata gtt gct gct 200
Asn Asn Gly Gln Lys Thr Phe Asp Phe Trp Lys Asp Ile Val Ala Ala
35 40 45
ata caa cac aat tat aaa atg tca gct ttt aag gaa aac tgt gga ata 248
Ile Gln His Asn Tyr Lys Met Ser Ala Phe Lys Glu Asn Cys Gly Ile
50 55 60 65
tat ttt cca gaa ata aaa aga gat cca ggc aga tat tta cat agt tgt 296
Tyr Phe Pro Glu Ile Lys Arg Asp Pro Gly Arg Tyr Leu His Ser Cys
70 75 80
cct gaa tct gtg aaa aaa tgg ctt cga cag cta aag aat gct ggg aaa 344
Pro Glu Ser Val Lys Lys Trp Leu Arg Gln Leu Lys Asn Ala Gly Lys
85 90 95
att ctt ctg tta att acc agt tct cac agt gat tac tgt aga ctt ctc 392
Ile Leu Leu Leu Ile Thr Ser Ser His Ser Asp Tyr Cys Arg Leu Leu
100 105 110
tgc gaa tat att ctt ggg aat gat ttt aca gac ctt ttt gac att gtg 440
Cys Glu Tyr Ile Leu Gly Asn Asp Phe Thr Asp Leu Phe Asp Ile Val
115 120 125
att aca aat gca ttg aag cct ggt ttc ttc tcc cac tta cca agt cag 488
Ile Thr Asn Ala Leu Lys Pro Gly Phe Phe Ser His Leu Pro Ser Gln
130 135 140 145
aga cct ttc cgg aca ctc gag aat gat gag gag cag gag gca ctg cca 536
Arg Pro Phe Arg Thr Leu Glu Asn Asp Glu Glu Gln Glu Ala Leu Pro
150 155 160
tct ctg gat aaa cct ggc tgg tac tcc caa ggg aac gct gtc cac ctc 584
Ser Leu Asp Lys Pro Gly Trp Tyr Ser Gln Gly Asn Ala Val His Leu
165 170 175
tat gaa ctt ctg aag aaa atg act ggc aaa cct gaa ccc aag gtt gtt 632
Tyr Glu Leu Leu Lys Lys Met Thr Gly Lys Pro Glu Pro Lys Val Val
180 185 190
tat ttt ggt gac agc atg cat tca gat att ttc cca gct cgt cac tat 680
Tyr Phe Gly Asp Ser Met His Ser Asp Ile Phe Pro Ala Arg His Tyr
195 200 205
agt aat tgg gag aca gtc ctc atc ctg gaa gaa ctc aga ggg gga 725
Ser Asn Trp Glu Thr Val Leu Ile Leu Glu Glu Leu Arg Gly Gly
210 215 220
tgaaggcacg aggagtcaga ggcctgagga gtcagagcct ctagagaaga aaggaaaata 785
tgagggacca aaagcaaaac ctttaaatac ttcatctaaa aaatggggct ctttttttat 845
tgattcagtt ttgggactgg aaaatacaga agactccttg gtttatacat ggtcttgtaa 905
gagaatcagt acttacagca ctattgcaat tccaagtatt gaagcaatcg cagaattacc 965
tctggactac aaatttacaa gattctcttc aagcaattca aaaacagctg gctactatcc 1025
aaatcctcca ctggtcttat caagtgatga gacactgata tccaaataag ttgtctttac 1085
tgaaaaatga agtgaagacc catatatgca gttaaaaaaa agttaatttt caaaaaatac 1145
tgtaaaagac tttaaggaac aagttttatt gaccaataag ttgatatttg tccataggtc 1205
tcctttctat aaatcatctt gatgtttaac aactcttatt atattaaaat ctcagtatcc 1265
taaaaaaaaa aaaaaaaaa 1284
<210>27
<211>224
<212>PRT
＜213〉homo sapiens (Homo sapiens)
<400>27
Met Ala Cys Arg Ser Gly Lys Tyr Tyr Phe Tyr Asp Asn Tyr Phe Asp
1 5 10 15
Leu Pro Gly Ala Leu Leu Cys Ala Arg Val Val Asp Tyr Leu Thr Lys
20 25 30
Leu Asn Asn Gly Gln Lys Thr Phe Asp Phe Trp Lys Asp Ile Val Ala
35 40 45
Ala Ile Gln His Asn Tyr Lys Met Ser Ala Phe Lys Glu Asn Cys Gly
50 55 60
Ile Tyr Phe Pro Glu Ile Lys Arg Asp Pro Gly Arg Tyr Leu His Ser
65 70 75 80
Cys Pro Glu Ser Val Lys Lys Trp Leu Arg Gln Leu Lys Asn Ala Gly
85 90 95
Lys Ile Leu Leu Leu Ile Thr Ser Ser His Ser Asp Tyr Cys Arg Leu
100 105 110
Leu Cys Glu Tyr Ile Leu Gly Asn Asp Phe Thr Asp Leu Phe Asp Ile
115 120 125
Val Ile Thr Asn Ala Leu Lys Pro Gly Phe Phe Ser His Leu Pro Ser
130 135 140
Gln Arg Pro Phe Arg Thr Leu Glu Asn Asp Glu Glu Gln Glu Ala Leu
145 150 155 160
Pro Ser Leu Asp Lys Pro Gly Trp Tyr Ser Gln Gly Asn Ala Val His
165 170 175
Leu Tyr Glu Leu Leu Lys Lys Met Thr Gly Lys Pro Glu Pro Lys Val
180 185 190
Val Tyr Phe Gly Asp Ser Met His Ser Asp Ile Phe Pro Ala Arg His
195 200 205
Tyr Ser Asn Trp Glu Thr Val Leu Ile Leu Glu Glu Leu Arg Gly Gly
210 215 220
<210>28
<211>1299
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<400>28
gccaggtaca gcaagtgggg cggcagctcc gaggaggtcc ccggagggcc ctggggacgc 60
tgggtgcact ggagcaggag acccctcttc ttggccctgg ctgtcctggt caccacagtc 120
ctttgggctg tgattctgag tatcctattg tccaaggcct ccacggagcg cgcggcgctg 180
cttgacggcc acgacctgct gaggacaaac gcctcgaagc agacggcggc gctgggtgcc 240
ctgaggagga ggtcggagac tgccacagct gctgctcggg gacgcaggcg cagctgcaga 300
ccacgcgcgc ggagcttggg gaggcgcagg cgaagctgat ggagcaggag agcgccctgc 360
gggaactgcg tgagcgcgtg acccagggct tggctgaagc cggcaggggc cgtgaggacg 420
tccgcactga gctgttccgg gcgctggagg ccgtgaggct ccagaacaac tcctgcgagc 480
cgtgccccac gtcgtggctg tccttcgagg gctcctgcta ctttttctct gtgccaaaga 540
cgacctgggc ggcggcgcag gatcactgcg cagatgccag cgcgcacctg gtgatcgttg 600
ggggcctgga tgagcagggc ttcctcactc ggaacacgcg tggccgtggt tactggctgg 660
gcctgagggc tgtgcgccat ctgggcaagg ttcagggcta ccagtgggtg gacggagtct 720
ctctcagctt cagccactgg aaccagggag agcccaatga cgcttggggg cgcgagaact 780
gtgtcatgat gctgcacacg gggctgtgga acgacgcacc gtgtgacagc gagaaggacg 840
gctggatctg tgagaaaaag gcacaactgc tgaccccgcc cagtgccctg gagccgcgcc 900
cattgcagca tgtcgtatcc tgggggctgc tcacctccct ggctcctgga gctgattgcc 960
aaagagtttt ttcttcctca tccaccgctg ctgagtctca gaaacacttg gcccaacata 1020
gccctgtcca gcccagtgcc tgggctctgg gacctccatg ccgacctcat cctaactcca 1080
ctcacgcaga cccaacctaa cctccactag ctccaaaatc cctgctcctg cgtccccgtg 1140
atatgcctcc acttctctcc ctaaccaagg ttaggtgact gaggactgga gctgtttggt 1200
tttctcgcat tttccaccaa actggaagct gtttttgcag cctgaggaag catcaataaa 1260
tatttgagaa atgaatccag gaaaaaaaaa aaaaaaaaa 1299
<210>29
<211>1299
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<220>
<221>CDS
<222>(339)..(1097)
<223>
<400>29
gccaggtaca gcaagtgggg cggcagctcc gaggaggtcc ccggagggcc ctggggacgc 60
tgggtgcact ggagcaggag acccctcttc ttggccctgg ctgtcctggt caccacagtc 120
ctttgggctg tgattctgag tatcctattg tccaaggcct ccacggagcg cgcggcgctg 180
cttgacggcc acgacctgct gaggacaaac gcctcgaagc agacggcggc gctgggtgcc 240
ctgaggagga ggtcggagac tgccacagct gctgctcggg gacgcaggcg cagctgcaga 300
ccacgcgcgc ggagcttggg gaggcgcagg cgaagctg atg gag cag gag agc gcc 356
Met Glu Gln Glu Ser Ala
1 5
ctg cgg gaa ctg cgt gag cgc gtg acc cag ggc ttg gct gaa gcc ggc 404
Leu Arg Glu Leu Arg Glu Arg Val Thr Gln Gly Leu Ala Glu Ala Gly
10 15 20
agg ggc cgt gag gac gtc cgc act gag ctg ttc cgg gcg ctg gag gcc 452
Arg Gly Arg Glu Asp Val Arg Thr Glu Leu Phe Arg Ala Leu Glu Ala
25 30 35
gtg agg ctc cag aac aac tcc tgc gag ccg tgc ccc acg tcg tgg ctg 500
Val Arg Leu Gln Asn Asn Ser Cys Glu Pro Cys Pro Thr Ser Trp Leu
40 45 50
tcc ttc gag ggc tcc tgc tac ttt ttc tct gtg cca aag acg acc tgg 548
Ser Phe Glu Gly Ser Cys Tyr Phe Phe Ser Val Pro Lys Thr Thr Trp
55 60 65 70
gcg gcg gcg cag gat cac tgc gca gat gcc agc gcg cac ctg gtg atc 596
Ala Ala Ala Gln Asp His Cys Ala Asp Ala Ser Ala His Leu Val Ile
75 80 85
gtt ggg ggc ctg gat gag cag ggc ttc ctc act cgg aac acg cgt ggc 644
Val Gly Gly Leu Asp Glu Gln Gly Phe Leu Thr Arg Asn Thr Arg Gly
90 95 100
cgt ggt tac tgg ctg ggc ctg agg gct gtg cgc cat ctg ggc aag gtt 692
Arg Gly Tyr Trp Leu Gly Leu Arg Ala Val Arg His Leu Gly Lys Val
105 110 115
cag ggc tac cag tgg gtg gac gga gtc tct ctc agc ttc agc cac tgg 740
Gln Gly Tyr Gln Trp Val Asp Gly Val Ser Leu Ser Phe Ser His Trp
120 125 130
aac cag gga gag ccc aat gac gct tgg ggg cgc gag aac tgt gtc atg 788
Asn Gln Gly Glu Pro Asn Asp Ala Trp Gly Arg Glu Asn Cys Val Met
135 140 145 150
atg ctg cac acg ggg ctg tgg aac gac gca ccg tgt gac agc gag aag 836
Met Leu His Thr Gly Leu Trp Asn Asp Ala Pro Cys Asp Ser Glu Lys
155 160 165
gac ggc tgg atc tgt gag aaa aag gca caa ctg ctg acc ccg ccc agt 884
Asp Gly Trp Ile Cys Glu Lys Lys Ala Gln Leu Leu Thr Pro Pro Ser
170 175 180
gcc ctg gag ccg cgc cca ttg cag cat gtc gta tcc tgg ggg ctg ctc 932
Ala Leu Glu Pro Arg Pro Leu Gln His Val Val Ser Trp Gly Leu Leu
185 190 195
acc tcc ctg gct cct gga gct gat tgc caa aga gtt ttt tct tcc tca 980
Thr Ser Leu Ala Pro Gly Ala Asp Cys Gln Arg Val Phe Ser Ser Ser
200 205 210
tcc acc gct gct gag tct cag aaa cac ttg gcc caa cat agc cct gtc 1028
Ser Thr Ala Ala Glu Ser Gln Lys His Leu Ala Gln His Ser Pro Val
215 220 225 230
cag ccc agt gcc tgg gct ctg gga cct cca tgc cga cct cat cct aac 1076
Gln Pro Ser Ala Trp Ala Leu Gly Pro Pro Cys Arg Pro His Pro Asn
235 240 245
tcc act cac gca gac cca acc taacctccac tagctccaaa atccctgctc 1127
Ser Thr His Ala Asp Pro Thr
250
ctgcgtcccc gtgatatgcc tccacttctc tccctaacca aggttaggtg actgaggact 1187
ggagctgttt ggttttctcg cattttccac caaactggaa gctgtttttg cagcctgagg 1247
aagcatcaat aaatatttga gaaatgaatc caggaaaaaa aaaaaaaaaa aa 1299
<210>30
<211>253
<212>PRT
＜213〉homo sapiens (Homo sapiens)
<400>30
Met Glu Gln Glu Ser Ala Leu Arg Glu Leu Arg Glu Arg Val Thr Gln
1 5 10 15
Gly Leu Ala Glu Ala Gly Arg Gly Arg Glu Asp Val Arg Thr Glu Leu
20 25 30
Phe Arg Ala Leu Glu Ala Val Arg Leu Gln Asn Asn Ser Cys Glu Pro
35 40 45
Cys Pro Thr Ser Trp Leu Ser Phe Glu Gly Ser Cys Tyr Phe Phe Ser
50 55 60
Val Pro Lys Thr Thr Trp Ala Ala Ala Gln Asp His Cys Ala Asp Ala
65 70 75 80
Ser Ala His Leu Val Ile Val Gly Gly Leu Asp Glu Gln Gly Phe Leu
85 90 95
Thr Arg Asn Thr Arg Gly Arg Gly Tyr Trp Leu Gly Leu Arg Ala Val
100 105 110
Arg His Leu Gly Lys Val Gln Gly Tyr Gln Trp Val Asp Gly Val Ser
115 120 125
Leu Ser Phe Ser His Trp Asn Gln Gly Glu Pro Asn Asp Ala Trp Gly
130 135 140
Arg Glu Asn Cys Val Met Met Leu His Thr Gly Leu Trp Asn Asp Ala
145 150 155 160
Pro Cys Asp Ser Glu Lys Asp Gly Trp Ile Cys Glu Lys Lys Ala Gln
165 170 175
Leu Leu Thr Pro Pro Ser Aia Leu Glu Pro Arg Pro Leu Gln His Val
180 185 190
Val Ser Trp Gly Leu Leu Thr Ser Leu Ala Pro Gly Ala Asp Cys Gln
195 200 205
Arg Val Phe Ser Ser Ser Ser Thr Ala Ala Glu Ser Gln Lys His Leu
210 215 220
Ala Gln His Ser Pro Val Gln Pro Ser Ala Trp Ala Leu Gly Pro Pro
225 230 235 240
Cys Arg Pro His Pro Asn Ser Thr His Ala Asp Pro Thr
245 250
<210>31
<211>1237
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<400>31
gatccccgcc aggcatcctc aaatccatca tgaagaagag agacggcaca cctggtgccc 60
aacccagctc cggacccaag agcctgcagt ttgttggggt cctcaacgga gagtgagcgc 120
ctttcccctc ctgtggcagc ttctgccggg acatagactg gggttggaac cccagctctg 180
cccctctact ggcagcgtgg tctgggcaat cctcagtttc ctcatcgtta aatgggaacg 240
gccacaccca catcgcagga ctccagaacg agcccacagg ggaggtttag cagacacctc 300
ccaccctgcc cccaggtacg agagctcctc cagcgaggac gccagcgaca gcatggcgac 360
agcgagaacg gtggcgccga gcccccgggt agctcctcgg gctccgggga tgacagcggc 420
gggggatccg actcgggcac ccctggccct cccagcggcg gggacatccg ggaccctgag 480
cccgaggcgg aggcagagcc tcagcaggtg gcacagggga ggtgagcggc gctcgctagt 540
tgtttggaga ggaggcggct gccctcctcc tggtcggcgc tgtccccgat ccatcctgag 600
tctctcctgg cctcctctgc aggtgcgagc tgagcccgcg tctgaaggag gcgtgcgtag 660
cgctgcagcg gcagctgagc cggccccgcg gagtaccagc gacggcggcg cagtgcgcct 720
cgtggcccag gagtggtttc gagtgtccag ccagcggcgc tctcaggcgg agcccgtggc 780
caggatgctg gaaggggtga ggcgcctggg acccgaactg ctggcgcacg tggtgaacct 840
ggcggatggc aacgggaaca cggccctgca ctacagtgtg tcccacggga acctggccat 900
cgcaagcctg ctcctggata cgggtcagag ccaagggagg gtgggtggac accaggaaat 960
gggtgggggg agagggcagg ggctgaccta ggctcaaaga ctctggagag gaaagcagag 1020
aatggctgtc cagcacaggg caccactcct ccttgagttt attttatttt attttaattt 1080
tattatttta ttttatttta ttttatttta ttttattttt gagacggagt ttcacactgt 1140
caccagggag gctgcagtga gccgagattg tggcattgca ctccagcctg ggtgacaggg 1200
cgagactctg tcccagaaaa aaaaaaaaaa aaaaaaa 1237
<210>32
<211>1237
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<220>
<221>CDS
<222>(353)..(988)
<223>
<400>32
gatccccgcc aggcatcctc aaatccatca tgaagaagag agacggcaca cctggtgccc 60
aacccagctc cggacccaag agcctgcagt ttgttggggt cctcaacgga gagtgagcgc 120
ctttcccctc ctgtggcagc ttctgccggg acatagactg gggttggaac cccagctctg 180
cccctctact ggcagcgtgg tctgggcaat cctcagtttc ctcatcgtta aatgggaacg 240
gccacaccca catcgcagga ctccagaacg agcccacagg ggaggtttag cagacacctc 300
ccaccctgcc cccaggtacg agagctcctc cagcgaggac gccagcgaca gc atg gcg 358
Met Ala
1
aca gcg aga acg gtg gcg ccg agc ccc cgg gta gct cct cgg gct ccg 406
Thr Ala Arg Thr Val Ala Pro Ser Pro Arg Val Ala Pro Arg Ala Pro
5 10 15
ggg atg aca gcg gcg ggg gat ccg act cgg gca ccc ctg gcc ctc cca 454
Gly Met Thr Ala Ala Gly Asp Pro Thr Arg Ala Pro Leu Ala Leu Pro
20 25 30
gcg gcg ggg aca tcc ggg acc ctg agc ccg agg cgg agg cag agc ctc 502
Ala Ala Gly Thr Ser Gly Thr Leu Ser Pro Arg Arg Arg Gln Ser Leu
35 40 45 50
agc agg tgg cac agg gga ggt gag cgg cgc tcg cta gtt gtt tgg aga 550
Ser Arg Trp His Arg Gly Gly Glu Arg Arg Ser Leu Val Val Trp Arg
55 60 65
gga ggc ggc tgc cct cct cct ggt cgg cgc tgt ccc cga tcc atc ctg 598
Gly Gly Gly Cys Pro Pro Pro Gly Arg Arg Cys Pro Arg Ser Ile Leu
70 75 80
agt ctc tcc tgg cct cct ctg cag gtg cga gct gag ccc gcg tct gaa 646
Ser Leu Ser Trp Pro Pro Leu Gln Val Arg Ala Glu Pro Ala Ser Glu
85 90 95
gga ggc gtg cgt agc gct gca gcg gca gct gag ccg gcc ccg cgg agt 694
Gly Gly Val Arg Ser Ala Ala Ala Ala Ala Glu Pro Ala Pro Arg Ser
100 105 110
acc agc gac ggc ggc gca gtg cgc ctc gtg gcc cag gag tgg ttt cga 742
Thr Ser Asp Gly Gly Ala Val Arg Leu Val Ala Gln Glu Trp Phe Arg
115 120 125 130
gtg tcc agc cag cgg cgc tct cag gcg gag ccc gtg gcc agg atg ctg 790
Val Ser Ser Gln Arg Arg Ser Gln Ala Glu Pro Val Ala Arg Met Leu
135 140 145
gaa ggg gtg agg cgc ctg gga ccc gaa ctg ctg gcg cac gtg gtg aac 838
Glu Gly Val Arg Arg Leu Gly Pro Glu Leu Leu Ala His Val Val Asn
150 155 160
ctg gcg gat ggc aac ggg aac acg gcc ctg cac tac agt gtg tcc cac 886
Leu Ala Asp Gly Asn Gly Asn Thr Ala Leu His Tyr Ser Val Ser His
165 170 175
ggg aac ctg gcc atc gca agc ctg ctc ctg gat acg ggt cag agc caa 934
Gly Asn Leu Ala Ile Ala Ser Leu Leu Leu Asp Thr Gly Gln Ser Gln
180 185 190
ggg agg gtg ggt gga cac cag gaa atg ggt ggg ggg aga ggg cag ggg 982
Gly Arg Val Gly Gly His Gln Glu Met Gly Gly Gly Arg Gly Gln Gly
195 200 205 210
ctg acc taggctcaaa gactctggag aggaaagcag agaatggctg tccagcacag 1038
Leu Thr
ggcaccactc ctccttgagt ttattttatt ttattttaat tttattattt tattttattt 1098
tattttattt tattttattt ttgagacgga gtttcacact gtcaccaggg aggctgcagt 1158
gagccgagat tgtggcattg cactccagcc tgggtgacag ggcgagactc tgtcccagaa 1218
aaaaaaaaaa aaaaaaaaa 1237
<210>33
<211>212
<212>PRT
＜213〉homo sapiens (Homo sapiens)
<400>33
Met Ala Thr Ala Arg Thr Val Ala Pro Ser Pro Arg Val Ala Pro Arg
1 5 10 15
Ala Pro Gly Met Thr Ala Ala Gly Asp Pro Thr Arg Ala Pro Leu Ala
20 25 30
Leu Pro Ala Ala Gly Thr Ser Gly Thr Leu Ser Pro Arg Arg Arg Gln
35 40 45
Ser Leu Ser Arg Trp His Arg Gly Gly Glu Arg Arg Ser Leu Val Val
50 55 60
Trp Arg Gly Gly Gly Cys Pro Pro Pro Gly Arg Arg Cys Pro Arg Ser
65 70 75 80
Ile Leu Ser Leu Ser Trp Pro Pro Leu Gln Val Arg Ala Glu Pro Ala
85 90 95
Ser Glu Gly Gly Val Arg Ser Ala Ala Ala Ala Ala Glu Pro Ala Pro
100 105 110
Arg Ser Thr Ser Asp Gly Gly Ala Val Arg Leu Val Ala Gln Glu Trp
115 120 125
Phe Arg Val Ser Ser Gln Arg Arg Ser Gln Ala Glu Pro Val Ala Arg
130 135 140
Met Leu Glu Gly Val Arg Arg Leu Gly Pro Glu Leu Leu Ala His Val
145 150 155 160
Val Asn Leu Ala Asp Gly Asn Gly Asn Thr Ala Leu His Tyr Ser Val
165 170 175
Ser His Gly Asn Leu Ala Ile Ala Ser Leu Leu Leu Asp Thr Gly Gln
180 185 190
Ser Gln Gly Arg Val Gly Gly His Gln Glu Met Gly Gly Gly Arg Gly
195 200 205
Gln Gly Leu Thr
210
<210>34
<211>1320
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<400>34
ggcggcgtcc aagggaggtt gagggctctg aggaggcgtt gagaggtttc cgtacagccc 60
gaccgtgcgg ctttggggat cccatcgctc tgtgtttcct gctccaggtt tcgcgtctcg 120
catcttccca gaccctcggg cgcgatgtgg aggagctgcc tccggctgcg ggacggggga 180
cgccgtctcc tgaatcggcc ggcgggtggc cccagcgctt ctatgagtcc ggggccaacc 240
atcccgtctc cagcccgggc ttacgccccg ccgacagaaa ggaagaggtt ttatcagaat 300
gtcagcatca cacagggtga aggtggcttt gagataaacc tggaccacag gaagctgaaa 360
actccccaag ccaagctctt taccgtcccc agcgaggccc tggcattgca gtggctactg 420
agtgggattc ccagcaggat accatcaagt actacaccat gcacctgacc acattgtgca 480
acacatcatt ggacaaccca acccagagaa acaaggatca gctgatccgg gcagccgtga 540
agtttctgga caccgacacc atctgctaca gggtggagga gcccgagaca ttagtggaac 600
ttcaaaggaa tgagtgggat ccaatcatcg aatgggctga gaaaagatac ggcgtggaga 660
tcagctcctc caccagcata atgggaccca gcatccctgc caaaactcgg gaggtgctcg 720
tcagccacct ggcatcttac aacacatggg ctttacaagg gattgagttt gtagctgccc 780
agctcaagtc catggtgcta accttgggcc tgattgacct gcgcctgaca gtggagcagg 840
ccgtgctgct gtcacgcctg gaggaggagt accagatcca gaagtggggc aacattgagt 900
gggcccatga ctatgagctg caggagctgc gggcccgcac cgccgccggc accctcttca 960
tccatctctg ctccgagagc accacagtca agcacaagct cctgaaggag tgaggcctgg 1020
gcagagcaca ctcagcagga tagaggcagt gcagccacag ctcccccggc cttcagggct 1080
ccccagcctg tggggctggc ttccttggct tttggggact cggccttagc gtcaccctga 1140
gattcccccc gagacacagt gcgctagtac ggctgtccgg aggtcagcct gatttcaacc 1200
caggtgcccc tggcctggcc agcagtgaat gtaggagatg aattgtgcaa gtgactttct 1260
ctcgactctg attttattaa atatttctcc acccgggaaa aaaaaaaaaa aaaaaaaaaa 1320
<210>35
<211>1320
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<220>
<221>CDS
<222>(459)..(1010)
<223>
<400>35
ggcggcgtcc aagggaggtt gagggctctg aggaggcgtt gagaggtttc cgtacagccc 60
gaccgtgcgg ctttggggat cccatcgctc tgtgtttcct gctccaggtt tcgcgtctcg 120
catcttccca gaccctcggg cgcgatgtgg aggagctgcc tccggctgcg ggacggggga 180
cgccgtctcc tgaatcggcc ggcgggtggc cccagcgctt ctatgagtcc ggggccaacc 240
atcccgtctc cagcccgggc ttacgccccg ccgacagaaa ggaagaggtt ttatcagaat 300
gtcagcatca cacagggtga aggtggcttt gagataaacc tggaccacag gaagctgaaa 360
actccccaag ccaagctctt taccgtcccc agcgaggccc tggcattgca gtggctactg 420
agtgggattc ccagcaggat accatcaagt actacacc atg cac ctg acc aca ttg 476
Met His Leu Thr Thr Leu
1 5
tgc aac aca tca ttg gac aac cca acc cag aga aac aag gat cag ctg 524
Cys Asn Thr Ser Leu Asp Asn Pro Thr Gln Arg Asn Lys Asp Gln Leu
10 15 20
atc cgg gca gcc gtg aag ttt ctg gac acc gac acc atc tgc tac agg 572
Ile Arg Ala Ala Val Lys Phe Leu Asp Thr Asp Thr Ile Cys Tyr Arg
25 30 35
gtg gag gag ccc gag aca tta gtg gaa ctt caa agg aat gag tgg gat 620
Val Glu Glu Pro Glu Thr Leu Val Glu Leu Gln Arg Asn Glu Trp Asp
40 45 50
cca atc atc gaa tgg gct gag aaa aga tac ggc gtg gag atc agc tcc 668
Pro Ile Ile Glu Trp Ala Glu Lys Arg Tyr Gly Val Glu Ile Ser Ser
55 60 65 70
tcc acc agc ata atg gga ccc agc atc cct gcc aaa act cgg gag gtg 716
Ser Thr Ser Ile Met Gly Pro Ser Ile Pro Ala Lys Thr Arg Glu Val
75 80 85
ctc gtc agc cac ctg gca tct tac aac aca tgg gct tta caa ggg att 764
Leu Val Ser His Leu Ala Ser Tyr Asn Thr Trp Ala Leu Gln Gly Ile
90 95 100
gag ttt gta gct gcc cag ctc aag tcc atg gtg cta acc ttg ggc ctg 812
Glu Phe Val Ala Ala Gln Leu Lys Ser Met Val Leu Thr Leu Gly Leu
105 110 115
att gac ctg cgc ctg aca gtg gag cag gcc gtg ctg ctg tca cgc ctg 860
Ile Asp Leu Arg Leu Thr Val Glu Gln Ala Val Leu Leu Ser Arg Leu
120 125 130
gag gag gag tac cag atc cag aag tgg ggc aac att gag tgg gcc cat 908
Glu Glu Glu Tyr Gln Ile Gln Lys Trp Gly Asn Ile Glu Trp Ala His
135 140 145 150
gac tat gag ctg cag gag ctg cgg gcc cgc acc gcc gcc ggc acc ctc 956
Asp Tyr Glu Leu Gln Glu Leu Arg Ala Arg Thr Ala Ala Gly Thr Leu
155 160 165
ttc atc cat ctc tgc tcc gag agc acc aca gtc aag cac aag ctc ctg 1004
Phe Ile His Leu Cys Ser Glu Ser Thr Thr Val Lys His Lys Leu Leu
170 175 180
aag gag tgaggcctgg gcagagcaca ctcagcagga tagaggcagt gcagccacag 1060
Lys Glu
ctcccccggc cttcagggct ccccagcctg tggggctggc ttccttggct tttggggact 1120
cggccttagc gtcaccctga gattcccccc gagacacagt gcgctagtac ggctgtccgg 1180
aggtcagcct gatttcaacc caggtgcccc tggcctggcc agcagtgaat gtaggagatg 1240
aattgtgcaa gtgactttct ctcgactctg attttattaa atatttctcc acccgggaaa 1300
aaaaaaaaaa aaaaaaaaaa 1320
<210>36
<211>184
<212>PRT
＜213〉homo sapiens (Homo sapiens)
<400>36
Met His Leu Thr Thr Leu Cys Asn Thr Ser Leu Asp Asn Pro Thr Gln
1 5 10 15
Arg Asn Lys Asp Gln Leu Ile Arg Ala Ala Val Lys Phe Leu Asp Thr
20 25 30
Asp Thr Ile Cys Tyr Arg Val Glu Glu Pro Glu Thr Leu Val Glu Leu
35 40 45
Gln Arg Asn Glu Trp Asp Pro Ile Ile Glu Trp Ala Glu Lys Arg Tyr
50 55 60
Gly Val Glu Ile Ser Ser Ser Thr Ser Ile Met Gly Pro Ser Ile Pro
65 70 75 80
Ala Lys Thr Arg Glu Val Leu Val Ser His Leu Ala Ser Tyr Asn Thr
85 90 95
Trp Ala Leu Gln Gly Ile Glu Phe Val Ala Ala Gln Leu Lys Ser Met
100 105 110
Val Leu Thr Leu Gly Leu Ile Asp Leu Arg Leu Thr Val Glu Gln Ala
115 120 125
Val Leu Leu Ser Arg Leu Glu Glu Glu Tyr Gln Ile Gln Lys Trp Gly
130 135 140
Asn Ile Glu Trp Ala His Asp Tyr Glu Leu Gln Glu Leu Arg Ala Arg
145 150 155 160
Thr Ala Ala Gly Thr Leu Phe Ile His Leu Cys Ser Glu Ser Thr Thr
165 170 175
Val Lys His Lys Leu Leu Lys Glu
180
<210>37
<211>1205
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<400>37
gatccaccgc ggcccggggt ggagaggtgg gggcgcagga ggaggggcac acgggactcg 60
ggcccagagc cgggggcggc tccgaggctg ggggccggga ttgggagccg gagcactggg 120
gcccaggcgt ttgcggacgt agcgcaacgg acagccggga ccgccccagc ccggccgacc 180
atgaactcgg gacgcgagcc ccgaacaccc cggacactct taagcatcgc agacatccta 240
gccccgcgca tggtcccccg agcaccctct gcgccgcagc ttccagagtc gggtccgggt 300
ccaacgtcgc cgctgtgcgc gctggaggag ctgactagta aaactttccg cggacttgac 360
gcgcgcgctc tgcagccctc tgaagggcgg gcaggtccgg acgcgctggg ccctggtccc 420
ttcggccgca aacggcgcaa gtcacgcact gcgttcaccg cgcaacaggt gctggagctg 480
gagcggcgct tcgtcttcca gaagtacctg gcgccgtccg agcgagacgg gctagctacg 540
cgactcggcc tggccaacgc gcaggtggtc acttggttcc agaaccggcg agccaagctc 600
aagcgcgatg tggaggagat gcgcgccgac gtcgcctcgc tacgcgcgtt gtccccggaa 660
gtcctgtgca gcttagcact gcccgagggc gctccagatc ccggcctctg cctcggccct 720
gccggccctg actcccggcc ccacctgtca gacgaggaga tacaggtgga cgattgaaga 780
caaagccgcc gccaatcctg ggctctgggg ccctggactc ctcacctcgc gctctgcctc 840
tggccagagt tccagggtgg aggaaggagg tccacttggg cctcttccgg cccacagtcc 900
agacgctcac ctttcccggt ttttttgtaa gtttgttttg ttgtctgaga cagggcctcg 960
ctctgtcgcc caggctggag tgccgtggag cgatcaccgc tcactgcagt cgcgacctcc 1020
tgggctcaag cgatcctcct gcctcaacct cccgactagc tggcattaca ggcgtgcagc 1080
accaccccag gctaatttaa aaaacttttt tttttagaga ggaggtcccg ctatgttgtc 1140
caggctactt tcccaatatt tgagaataaa gtcgagactc tgccgcaaaa aaaaaaaaaa 1200
aaaaa 1205
<210>38
<211>1205
<212>DNA
＜213〉homo sapiens (Homo sapiens)
<220>
<221>CDS
<222>(181)..(774)
<223>
<400>38
gatccaccgc ggcccggggt ggagaggtgg gggcgcagga ggaggggcac acgggactcg 60
ggcccagagc cgggggcggc tccgaggctg ggggccggga ttgggagccg gagcactggg 120
gcccaggcgt ttgcggacgt agcgcaacgg acagccggga ccgccccagc ccggccgacc 180
atg aac tcg gga cgc gag ccc cga aca ccc cgg aca ctc tta agc atc 228
Met Asn Ser Gly Arg Glu Pro Arg Thr Pro Arg Thr Leu Leu Ser Ile
1 5 10 15
gca gac atc cta gcc ccg cgc atg gtc ccc cga gca ccc tct gcg ccg 276
Ala Asp Ile Leu Ala Pro Arg Met Val Pro Arg Ala Pro Ser Ala Pro
20 25 30
cag ctt cca gag tcg ggt ccg ggt cca acg tcg ccg ctg tgc gcg ctg 324
Gln Leu Pro Glu Ser Gly Pro Gly Pro Thr Ser Pro Leu Cys Ala Leu
35 40 45
gag gag ctg act agt aaa act ttc cgc gga ctt gac gcg cgc gct ctg 372
Glu Glu Leu Thr Ser Lys Thr Phe Arg Gly Leu Asp Ala Arg Ala Leu
50 55 60
cag ccc tct gaa ggg cgg gca ggt ccg gac gcg ctg ggc cct ggt ccc 420
Gln Pro Ser Glu Gly Arg Ala Gly Pro Asp Ala Leu Gly Pro Gly Pro
65 70 75 80
ttc ggc cgc aaa cgg cgc aag tca cgc act gcg ttc acc gcg caa cag 468
Phe Gly Arg Lys Arg Arg Lys Ser Arg Thr Ala Phe Thr Ala Gln Gln
85 90 95
gtg ctg gag ctg gag cgg cgc ttc gtc ttc cag aag tac ctg gcg ccg 516
Val Leu Glu Leu Glu Arg Arg Phe Val Phe Gln Lys Tyr Leu Ala Pro
100 105 110
tcc gag cga gac ggg cta gct acg cga ctc ggc ctg gcc aac gcg cag 564
Ser Glu Arg Asp Gly Leu Ala Thr Arg Leu Gly Leu Ala Asn Ala Gln
115 120 125
gtg gtc act tgg ttc cag aac cgg cga gcc aag ctc aag cgc gat gtg 612
Val Val Thr Trp Phe Gln Asn Arg Arg Ala Lys Leu Lys Arg Asp Val
130 135 140
gag gag atg cgc gcc gac gtc gcc tcg cta cgc gcg ttg tcc ccg gaa 660
Glu Glu Met Arg Ala Asp Val Ala Ser Leu Arg Ala Leu Ser Pro Glu
145 150 155 160
gtc ctg tgc agc tta gca ctg ccc gag ggc gct cca gat ccc ggc ctc 708
Val Leu Cys Ser Leu Ala Leu Pro Glu Gly Ala Pro Asp Pro Gly Leu
165 170 175
tgc ctc ggc cct gcc ggc cct gac tcc cgg ccc cac ctg tca gac gag 756
Cys Leu Gly Pro Ala Gly Pro Asp Ser Arg Pro His Leu Ser Asp Glu
180 185 190
gag ata cag gtg gac gat tgaagacaaa gccgccgcca atcctgggct 804
Glu Ile Gln Val Asp Asp
195
ctggggccct ggactcctca cctcgcgctc tgcctctggc cagagttcca gggtggagga 864
aggaggtcca cttgggcctc ttccggccca cagtccagac gctcaccttt cccggttttt 924
ttgtaagttt gttttgttgt ctgagacagg gcctcgctct gtcgcccagg ctggagtgcc 984
gtggagcgat caccgctcac tgcagtcgcg acctcctggg ctcaagcgat cctcctgcct 1044
caacctcccg actagctggc attacaggcg tgcagcacca ccccaggcta atttaaaaaa 1104
cttttttttt tagagaggag gtcccgctat gttgtccagg ctactttccc aatatttgag 1164
aataaagtcg agactctgcc gcaaaaaaaa aaaaaaaaaa a 1205
<210>39
<211>198
<212>PRT
＜213〉homo sapiens (Homo sapiens)
<400>39
Met Asn Ser Gly Arg Glu Pro Arg Thr Pro Arg Thr Leu Leu Ser Ile
1 5 10 15
Ala Asp Ile Leu Ala Pro Arg Met Val Pro Arg Ala Pro Ser Ala Pro
20 25 30
Gln Leu Pro Glu Ser Gly Pro Gly Pro Thr Ser Pro Leu Cys Ala Leu
35 40 45
Glu Glu Leu Thr Ser Lys Thr Phe Arg Gly Leu Asp Ala Arg Ala Leu
50 55 60
Gln Pro Ser Glu Gly Arg Ala Gly Pro Asp Ala Leu Gly Pro Gly Pro
65 70 75 80
Phe Gly Arg Lys Arg Arg Lys Ser Arg Thr Ala Phe Thr Ala Gln Gln
85 90 95
Val Leu Glu Leu Glu Arg Arg Phe Val Phe Gln Lys Tyr Leu Ala Pro
100 105 110
Ser Glu Arg Asp Gly Leu Ala Thr Arg Leu Gly Leu Ala Asn Ala Gln
115 120 125
Val Val Thr Trp Phe Gln Asn Arg Arg Ala Lys Leu Lys Arg Asp Val
130 135 140
Glu Glu Met Arg Ala Asp Val Ala Ser Leu Arg Ala Leu Ser Pro Glu
145 150 155 160
Val Leu Cys Ser Leu Ala Leu Pro Glu Gly Ala Pro Asp Pro Gly Leu
165 170 175
Cys Leu Gly Pro Ala Gly Pro Asp Ser Arg Pro His Leu Ser Asp Glu
180 185 190
Glu Ile Gln Val Asp Asp
195
<210>40
<211>18
<212>DNA
＜213〉primer
<400>40
acccgagcca aggacacc 18
<210>41
<211>18
<212>DNA
＜213〉primer
<400>41
agaagggagg ggacacga 18
<210>42
<211>22
<212>DNA
＜213〉primer
<400>42
catttgaaaa gcatggtcct ag 22
<210>43
<211>18
<212>DNA
＜213〉primer
<400>43
ggaacgacgc ctcttact 18
<210>44
<211>22
<212>DNA
＜213〉primer
<400>44
aatcttcccg ttgctgtatg tg 22
<210>45
<211>18
<212>DNA
＜213〉primer
<400>45
ttcacggagc ctaccacc 18
<210>46
<211>19
<212>DNA
＜213〉primer
<400>46
tttagtgcct cccacccag 19
<210>47
<211>21
<212>DNA
＜213〉primer
<400>47
tgacccagaa gtgaagaacc c 21
<210>48
<211>18
<212>DNA
＜213〉primer
<400>48
caggggcaag gcaccatc 18
<210>49
<211>18
<212>DNA
＜213〉primer
<400>49
caagcgggtc acggtgca 18
<210>50
<211>22
<212>DNA
＜213〉primer
<400>50
ctagaagtgg aactgctggg tc 22
<210>51
<211>19
<212>DNA
＜213〉primer
<400>51
tgttttgttt acggggtcc 19
<210>52
<211>18
<212>DNA
＜213〉primer
<400>52
gcggctcctg ttgctcct 18
<210>53
<211>19
<212>DNA
＜213〉primer
<400>53
catcctgggc gtccctggt 19
<210>54
<211>18
<212>DNA
＜213〉primer
<400>54
accagaggtt gggaggca 18
<210>55
<211>20
<212>DNA
＜213〉primer
<400>55
gcttgacctt gtagaccagg 20
<210>56
<211>20
<212>DNA
＜213〉primer
<400>56
tggcaagaaa gagtggaagc 20
<210>57
<211>22
<212>DNA
＜213〉primer
<400>57
tgataggttt aggaggtgac ca 22
<210>58
<211>19
<212>DNA
＜213〉primer
<400>58
gccaggtaca gcaagtggg 19
<210>59
<211>20
<212>DNA
＜213〉primer
<400>59
caaaagagcg taaaaggtgg 20
<210>60
<211>19
<212>DNA
＜213〉primer
<400>60
gccaggcatc ctcaaatcc 19
<210>61
<211>19
<212>DNA
＜213〉primer
<400>61
tcactcggct ctaacaccg 19
<210>62
<211>19
<212>DNA
＜213〉primer
<400>62
ggctctgagg aggcgttga 19
<210>63
<211>18
<212>DNA
＜213〉primer
<400>63
aagttgggtc cacgggga 18
<210>64
<211>18
<212>DNA
＜213〉primer
<400>64
acgtagcgca acggacag 18
<210>65
<211>22
<212>DNA
＜213〉primer
<400>65
ttatttcagc tctgagacgg cg 22
Claims (9)
1. isolating people's albumen with promotion 3T3 cell transformation function is characterized in that it has the aminoacid sequence of the group of being selected from down: SEQ ID NO:3,6,9,12,15,18,21,24,27,30,33,36,39.
2. albumen as claimed in claim 1 is characterized in that, this albumen has the aminoacid sequence of the group of being selected from down: SEQ ID NO:3,6,9,12,15,18,21,24,27,36,39.
3. isolating polynucleotide is characterized in that, it is selected from down group:
(a) the proteic according to claim 1 polynucleotide of coding;
(b) with polynucleotide (a) complementary polynucleotide.
4. polynucleotide as claimed in claim 3 is characterized in that, the albumen of this polynucleotide encoding has the aminoacid sequence of the group of being selected from down: SEQ ID NO:3,6,9,12,15,18,21,24,27,36,39.
5. polynucleotide as claimed in claim 3 is characterized in that, the sequence of these polynucleotide is selected from down group:
SEQ ID NO:2,5,8,11,14,17,20,23,26,29,32,35,38 coding region sequence or full length sequence.
6. a carrier is characterized in that, it contains the described polynucleotide of claim 3.
7. a genetically engineered host cell is characterized in that, it is a kind of host cell that is selected from down group:
(a) host cell that transforms or transduce with the described carrier of claim 6;
(b) host cell that transforms or transduce with the described polynucleotide of claim 3.
8. a claim 1 is described has a proteic preparation method of people who promotes 3T3 cell transformation function, it is characterized in that this method comprises:
(a) being fit to express under the proteic condition of people with promotion 3T3 cell transformation function, cultivate the described host cell of claim 7;
(b) from culture, isolate people's albumen with promotion 3T3 cell transformation function.
9. an energy and claim 1 are described has the people's protein-specific bonded antibody that promotes 3T3 cell transformation function.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021369992A CN1230445C (en) | 2002-09-16 | 2002-09-16 | Novel human protein with function for promoting mouse NIH/313 cell transformation and coding sequence thereof |
| PCT/CN2003/000636 WO2004033493A1 (en) | 2002-08-07 | 2003-08-07 | Human protein for promoting transformation of 3t3 cell and its coding sequence |
| AU2003255095A AU2003255095A1 (en) | 2002-08-07 | 2003-08-07 | Human protein for promoting transformation of 3t3 cell and its coding sequence |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021369992A CN1230445C (en) | 2002-09-16 | 2002-09-16 | Novel human protein with function for promoting mouse NIH/313 cell transformation and coding sequence thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1483739A CN1483739A (en) | 2004-03-24 |
| CN1230445C true CN1230445C (en) | 2005-12-07 |
Family
ID=34146796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021369992A Expired - Fee Related CN1230445C (en) | 2002-08-07 | 2002-09-16 | Novel human protein with function for promoting mouse NIH/313 cell transformation and coding sequence thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1230445C (en) |
-
2002
- 2002-09-16 CN CNB021369992A patent/CN1230445C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1483739A (en) | 2004-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1592793A (en) | Hepatocellular carcinoma-related genes and polypeptides, and method for detecting hepatocellular carcinomas | |
| CN1170850C (en) | Human angiogenin-like protein and coding sequence and application thereof | |
| CN1169954C (en) | Human protein able to suppress growth of cancer cells and its coding sequence | |
| CN1230445C (en) | Novel human protein with function for promoting mouse NIH/313 cell transformation and coding sequence thereof | |
| CN1177048C (en) | Human protein with function of suppressing cancer cell growth and its coding sequence | |
| CN1177864C (en) | Novel human protein with expression difference in liver cancer tissue and its code sequence | |
| CN1199998C (en) | Human protein with suppression to cancer cell growth and its coding sequence | |
| CN1177049C (en) | Human protein with function of suppressing cancer cell growth and its coding sequence | |
| CN1169955C (en) | Human protein able to suppress growth of cancer cells and its coding sequence | |
| CN1155615C (en) | Human protein with cancer cell growth suppressing function and its coding sequence | |
| CN1199997C (en) | New human protein having mouse NIH/3T3 cell conversion promoting function and its code sequence | |
| CN1194989C (en) | Novel human protein able to suppress cancer cell growth and its coding sequence | |
| CN1209373C (en) | Human protein with suppression to cancer cell growth and its coding sequence | |
| CN1231496C (en) | Human protein with cancer cell growth suppressing function and its coding sequence | |
| CN1177050C (en) | Human protein with function of suppressing cancer cell growth and its coding sequence | |
| CN1169831C (en) | Human protein with cancer call growth suppressing function and its coding sequence | |
| CN1205225C (en) | Human protein with cancer inhibiting function and its coding sequence | |
| CN1169958C (en) | Human protein able to suppress growth of cancer cells and its coding sequence | |
| CN1170848C (en) | Novel human hepatoma associated protein and coding sequence thereof | |
| CN1169833C (en) | Human Protein with cancer inhibiting function and its coding sequence | |
| CN1194010C (en) | New human protein with the function of inhibiting cancer cell growth and its coding sequence | |
| CN1169956C (en) | Human protein able to suppress growth of cancer cells and its coding sequence | |
| CN1222616C (en) | Novel human protein with cancer-inhibiting function and coding sequence thereof | |
| CN1199994C (en) | New human protein with cancer cell growth inhibiting function and its coding sequence | |
| CN1199999C (en) | Human protein for promoting transform of 3T3 cell and its coding sequence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |